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ABSTRACT
Nucleosides and nucleotides are powerful building units for creating functional molecules
with novel properties. The structural and functional variations of these biomolecules have caused a
renaissance of nucleic acid chemistry and biology, and paved the way for fresh avenues in nucleic
acid research, including therapeutics, nucleic acid biology, structure-function studies, catalytic and
mechanistic analysis, and material science and nanotechnology.
Modified nucleic acids are instrumental in discovering functional oligonucleotides as significant biochemical and therapeutic agents. A variety of synthetic strategies have been developed to
design novel analogs with tunable physico-chemical properties, such as enhanced duplex stability,
binding affinity, nuclease resistance, bioavailability, and base-pair fidelity. These engineered nucleic
acids are useful structural, functional, and mechanistic probes for disease detection, molecular

sensing, and fundamental understanding of the structures and biological functions of nucleic acids
(DNA and RNA).
The structural, functional and spectroscopic repertoire of the nucleic acids can be further
enhanced by strategic substitution of the oxygen atoms with selenium atoms. Selenium
derivatization of nucleic acids generates modified biopolymers with unique structural and functional features that make them strong contenders for biochemical and biophysical research. The
substitution of oxygen with selenium in the nucleobases permits a search for novel aspects of nucleic acid base-pairing and stacking interactions at the atomic level. Huang and co-workers have
demonstrated that the single-atom modified (SAM) nucleosides and nucleic acids, where a single
oxygen atom is strategically replaced with a selenium atom, are yellow colored and have over a 100
nm red-shift in the absorption maximum (1-3). With minimal structural perturbation, SAM nucleosides and nucleotides could be of immense significance in the detection and visualization of nucleic
acids. Selenium-derivatized nucleic acids (SeNAs) could also serve as imperative tools in the structural, functional and mechanistic studies of nucleic acids and their complexes with proteins, small
molecules, and/or metal ions.
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1
1.1

INTRODUCTION

Significance of Nucleic Acids

Nucleosides, nucleotides and oligonucleotides are of paramount significance with multifaceted and intricate roles in cell biology. Nucleic acids are the fundamental bio-macromolecules that
replicate, transcribe and translate genetic information. Virtually omnipresent, nucleic acids are the
storehouse of genetic information (4,5). For several decades they have generated curiosity about
the origin of life and nature’s preference for ribose- and deoxyribonucleic acids as the molecular
basis of life’s genetic systems (6). Thus, a detailed structural and functional analysis of nucleic acids
is essential to the knowledge of life. However, their potential as functional bio-molecules has been
greatly undermined. Nucleosides and nucleotides are significant and powerful building blocks. They
can be easily modeled and chemically functionalized at various positions, with diverse functional
groups, for creating functional molecules with novel properties. Modified analogs, with tailored
properties, are potential candidates for novel drug therapies and effective biological tools for the
fundamental understanding of diseases at molecular and genetic level (7-9). Both chemical and enzymatic approaches have been utilized to synthesize functionalized nucleic acids. The modification
of nucleic acids presents enormous opportunities for tailoring the properties and functions of these
bio-macromolecules, escalating their potential in biochemical and biomedical applications (10-20).
It is amazing how only five elements, namely oxygen (O), nitrogen (N), phosphorus (P), carbon (C) and hydrogen (H) [rarely sulfur (S) and selenium (Se)], create nucleic acids. However, their
functions have been limited by the combination of only four nucleotide building blocks. Therefore,
chemical modifications help in creating nucleic acids with tunable physico-chemical properties for
applications in catalysis, molecular binding and nucleic-acid labeling. The basic structure of a nucleotide consists of a base, a sugar and a phosphate group. All these three components have various
active sites (figure 1.1) which were, and still are, prime targets for chemical modification.

2

Figure 1.1 Probable sites for chemical modifications in DNAs and RNAs.

1.2

Single Atom Modification (SAM) in Nucleic Acids

Single atom modification in nucleic acids involves the atom-specific substitution of a single
nucleotide atom with another equivalent atom. Oxygen atoms are found in abundance in nucleic
acids. Therefore, atom specific replacement of oxygen with sulfur,selenium and tellurium (other
members of the chalcogen family), is a useful and successful chemical strategy to improve and tune
the biophysical and biochemical properties of nucleic acids. Compared to oxygen (atomic radius:
0.73 Å), they have larger atomic sizes (atomic radius of S: 1.02 Å, Se: 1.16 Å and Te: 1.40 Å) and
electron densities (21). These features offer distinctive and novel properties, without causing any
significant structural perturbation. The modified nucleic acids act as good structural mimics of the
corresponding oxo-nucleic acids. Figure 1.2 demonstrates the atom specific modification of oxygen
with sulfur and selenium on the nucleobase, sugar and phosphate backbone.
Sulfur is an interesting element with divergent chemical properties. It is widely found in a
broad array of natural biomolecules owing to its chemical and structural behavior. Sulfur is an essential element for all forms of life and is involved in various biochemical processes. In search of
bioactive compounds, a variety of modified oligonucleotides containing a sulfur atom on the sugar,
the nucleobase, or the phosphoryl group have been synthesized. Sulfur adds substantial functionality to nucleic acids, as a result of its structural and chemical versatility. Incorporation of sulfur in
nucleosides, nucleotides and nucleic acids can afford exclusive biological properties like increased
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metabolic stability and bioavailability, nuclease resistance, high hybridization, and decreased toxicity (22-32). These sulfur-derivatized oligonucleotides are valuable tools in understanding proteinnucleic acid interactions, nucleic acid structure-function relationship, and oligonucleotide therapy
(17,33-39).

(a)

(b)

Figure 1.2 Atom-specific replacement of oxygen with S and Se on (a) the nucleobase and (b) the sugar and phosphate
backbone. The asterisk (*) indicates the naturally occurring modifications.

Selenium is an essential element and a vital micronutrient for humans with potential antioxidant properties. It is present naturally in foods and soils, and is available via dietary supplements
(40-42). Analogous to sulfur, natural occurrence of selenium in tRNAs has been observed in certain
bacteria and mammals. The selenium nucleoside, identified as 5-[(methylamino)methyl]-2selenouridine (mnm5se2U), is often found at the first or wobble position of the anticodon loop of
tRNA (43,44). While the precise function of selenium at the C-2 position and the comprehensive
utility of Se-derivatized tRNAs are not delineated, this modification is essential for catalysis and
regulation and probably capable of augmenting translational efficiency and efficacy(45).Selenium
derivatization of nucleic acids generates the modified biopolymers with novel properties. Huang
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and co-workers have pioneered the synthesis and structure-function studies of seleniumderivatized (or -modified) nucleic acids (SeNA). Atom-specific selenium modification at different
positions in the nucleobase, sugar, and phosphate group has been achieved by Huang’s research
group along with other groups (46-65). Through different modifications in the nucleobase and sugar, it has been demonstrated that the presence of selenium atom facilitates crystallization and crystallographic phasing(46,47,66) to the extent that it has surpassed all other know approaches (like,
heavy-atomsoaking, co-crystallization, and halogen derivatization) for nucleic acid X-ray crystallography.The nucleosides, nucleotides and nucleic acids obtained by atom-specific substitution of oxygen with selenium serve as useful biophysical, structural, and mechanistic probes. The stability and
compatibility of the selenium functionality, with chemical and enzymatic synthesis, has made the
introduction and incorporation of selenium at different positions a reliable and useful technique.
Tellurium, a non-essential trace element, is toxic to humans and does not occur naturally in
any biomolecules. Tellurium, with larger size, lower electronegativity (Te: 2.0; Se: 2.55; S: 2.58) and
more metallic character, has distinctive chemical properties in comparison with sulfur and selenium (67). Owing to its exceptional physical, chemical and spectroscopic properties, tellurium compounds have recently garnered appreciable interest from the researchers in drug development and
diagnostics and in structure determination of proteins and nucleic acids. Atom-specific incorporation of tellurium into nucleic acids was pioneered by Huang and co-workers (68-70). Tellurium
functionality has been successfully introduced into different positions of the nucleobase and sugar(68-70). The thermal stability and X-ray crystallographic studies of the Te-DNA thus obtained reveals that the modified DNA is virtually identical to the native DNA in structure and stability.It is
likely that the presence of an electron-rich tellurium atom in a DNA base facilitates electron delocalization by donation of electrons to the relatively electron-deficient DNA duplexes. This phenomenon helps in direct DNA imaging without significant structural perturbation.In scanning tunneling
microscope (STM) imaging the Te-DNA duplexes exhibit higher visibility and conductivity and re-
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veal stronger topographic and current peaks than the corresponding native duplexes. Thus, by the
virtue of their unique optoelectronic properties, tellurium derivatized nucleic acids open a novel
approach towards the imaging of nucleic acids and their complexes with proteins and small molecules.
In other examples of atom specific mutagenesis of nucleic acids, halogen atoms are considered equivalent to hydrogen atoms. Although, the options for halogen replacement on the
nucleobase and sugar are limited (figure 1.3) compared with the sulfur and selenium modifications,
halogen-derivatized nucleic acids analogs are well applied in nucleic acid structure-function studies
and in drug discovery and development. Similar in size, fluorine is the closest mimic of the hydrogen atom when introduced in biomolecules. It offers minimal structural perturbation, along with
improved stability contributed by the stronger C—F bond. With 100 % isotopic abundance,

19F

qualifies for the ideal atomic label for probing the structure, conformation and dynamics of nucleic
acids via fluorine labeling and 19F-NMR(71-73). 19F-NMR has been extensively utilized for the investigating several fluoro-nucleobases: 5-fluorouridine in U/G wobble pair investigation (74), dynamics of hammerhead ribozyme(75); 5-fluorocytosine in base-flipping in HhaI methyltransferase–DNA
interactions (76); 2-fluoroadenosine in base-pairing interaction study (77). The 2'-F labels have
been successfully used for exploring DNA motifs and RNA folding pathways (78-81). The 2'-α-fluoro
labeled siRNAs, with improved thermostability and resistance towards nucleases, are strong contenders in siRNA therapeutics (82,83). The 2'-β-fluoro labeled nucleosides have potential antiviral
and anticancer activities (84-86).

6

Figure 1.3 Atom-specific replacement of hydrogen with halogens (F, Cl, Br or I) on nucleobase and sugar.

The applications of other halogen (chlorine, bromine or iodine) derivatized nucleic acids are
not as widespread as of fluoro-modified analogs. The most familiar chloro-modified analog, 2chloroadenosine has been explored for nuclease resistance studies (87), along with other potential
therapeutic applications(88-91). In general, bromine and iodine have been introduced into nucleic
acids via C-5-position of pyrimidine, C-8-position of purine, and C-2-position of adenosine. Analogous to selenium, bromine and iodine serve as anomalous scattering centers in X-ray crystallography via MAD (multi-wavelength anomalous diffraction) and SAD (single-wavelength anomalous
diffraction) and as isomorphous heavy atoms in MIR (multiple isomorphous replacement). The introduction of a single bromine or iodine-atom has resulted in several X-ray crystal structures (9297).Nevertheless, the halogen (heavy-atom) modified nucleic acid analogs present their own disadvantages: (i) the total possible locations on the nucleoside for halogen-derivatization are limited;
(ii) bromide and iodide being good leaving groups can be easily replaces when located at C-2' of the
sugar; (iii) halogen functionality is sensitive to X-ray irradiation, resulting in dehalogenation (Br
and I) and failure in structure determination (98,99); (iv) placement of bromine/iodine at C-8 of
purines causes rotation from anti- to syn-conformation resulting in structural perturbation (100102). Significant structural perturbation can also occur if the halogen modification is placed in the
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major-groove of the A-form double helix (103). Halogen-modified DNA/RNA also find application in
therapeutics (104,105).

Figure 1.4 Jablonski diagram: mechanism of fluorescence and phosphorescence.

1.3 Fluorescence Based Detection of Nucleic Acids
Fluorescence is the light emitted from a molecule after it has absorbed light of a different/shorter wavelength. Fluorescence is an intrinsic property. Fluorescence is generally studied in
highly conjugated polycyclic aromatic molecules. When the irradiating light is removed, fluorescence stops. But some molecules continue to emit longer-wavelength radiation, even after the removal of exciting radiation. This phenomenon is known as phosphorescence (106). Fluorescence
from a compound is dependent on several factors like pH, temperature, impurity and polarity of
solvent. In fluorescence spectroscopy, a photon of energy is absorbed by the fluorophore. This absorption of light by the molecule promotes an electron from its ground electronic state (S0) to one
of the vibrational levels in the excited electronic states (S1,S2,S3, etc.). The fluorophore rapidly deactivate to the lowest vibrational state of the excited electronic state (S1). This process is often visualized with a Jablonski diagram (figure 2.1). The molecule then drops down to one of the various vibrational levels of the ground electronic state again, emitting a photon in the process. The light thus
emitted is known as fluorescence.
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Fluorescence spectroscopy is of the most sensitive analytical techniques. Fluorescence
based tools have been valuable in studying the fundamental structure, folding, recognition, reactivity and dynamics of biomolecules in biological systems (107-113). As many of the biological macromolecules are inherently non-emissive, fluorescent analogs of the building blocks (carbohydrates,
phospholipids, fatty acids, amino acids and nucleosides) of biomolecules have been designed and
synthesized (114). Carbohydrates do not have any conjugated π-system and hence, lack any useful
absorption/emission feature. Therefore, significant structural modifications are necessary to bestow useful photo-physical properties. The biological membrane is a complex constitution of a diverse variety of constituents. The plethora of fluorescent probes, labels and methodologies available are dictated largely by their function and largely include non-covalent fluorescent membrane
probes (115-118), polar head group-labels (119-121) and lipophilic chain-labels (includes inchain, chain-end and on-chain labeling) (122-125). These fluorescent probes have greatly contributed to our understanding of various functions, properties, interactions and dynamics of the biological membranes. Fluorescence spectroscopy has also been instrumental in detecting and understanding the structure, function and dynamics of proteins and nucleic acids, especially under physiological conditions (126-135). Proteins play a central role in modern biology. Their recognition,
function and cell localization depends on their three-dimensional structure and susceptibility to
environmental factors. This dependency on structure limits the structural diversity of the aminoacid probes. The chromophores for fluorescent amino-acid probes are designed for specific applications like exploring conformational behavior, studying structural and functional behavior in varied
environments and, binding interactions with other molecules (114).
Although it has been overwhelmingly helpful in studying proteins, fluorescence spectroscopy has found limited use in nucleic acids due to their low fluorescence quantum yields. This presented a major challenge in the biophysical study of nucleic acids thereby initiating extensive
search for emissive nucleoside/nucleotide analogs. The purine and pyramidine bases present a fer-
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tile ground for diverse chemical modification with minimal structural and electronic perturbations
and varied photo-physical properties. With the advancement in the design and synthesis of fluorescent nucleoside mimics and surrogates, the contemporary landscape of fluorescent nucleic acids is
very vast. Chapter 2 of this dissertation illustrates a few examples of the various designs and the
resultant significance of fluorescent nucleoside analogs. The fluorescent analogs have a diverse
range of applications. These analogs can be easily incorporated into the oligonucleotides via standard syntheticmethods, without significant structural, chemical and electronic perturbations. The
resultant oligonucleotides serve as sensitive probes for investigating the conformational changes
and structural perturbations resulting from changes in the microenvironment. Due to their high
sensitivity and selectivity, the fluorescent analogs have minimal interference with the biological
system enabling an efficient visualization of DNA/RNA molecules, both in vivo and in vitro. This further helps in tracking the location, transportation and global conformational changes in nucleic acids and their complexes. All these advances have resulted in the widespread application of fluorescent mimics/probes in biophysical, biochemical and biomedical studies, disease diagnosis, and drug
development.
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2

SYNTHESIS AND OPTICAL STUDY OF 6-SELENO-2'-DEOXYGUANOSINE

Different nucleoside analogs, containing alternate or extended bases or covalently attached
fluorescent labels, have been designed and used to study the native nucleic acids. Fluorescent analogs of nucleic acid bases afford sensitive probes for exploring the structure, interactions, and dynamics of nucleic acids. Discussion of all the fluorescent nucleoside analogs is beyond the scope of
this dissertation. Therefore, this report includes only a few relevant examples.
2.1

Fluorescent Nucleoside Analogs: Early Examples

Nucleosides, the structural subunits of nucleic acids, are composed of a pentose sugar (ribose or deoxyribose) linked to a nucleobase (nitrogenous heterocyclic rings: purines and
pyramidines) via a beta-glycosidic bond. Naturally occurring nucleic acids are practically nonemissive in physiological conditions (136). However, strong acidic solutions (with pH as low as 1)
can induce weak fluorescence in native nucleobases like adenine and guanine (137-139). But, such
strong conditions are inapt for probing the nucleic acids and their interactions with other molecules. Such challenges propelled the nucleoside chemists to explore new emissive nucleoside analogs. Presently, the development of fluorescent nucleoside analogs is a rapidly evolving field.
The nucleobases (purines and pyramidines) present a fertile ground for diverse chemical
modifications where minimal molecular and electronic perturbation can dramatically alter the photo-physical characteristics such as molar absorptivity, quantum yield, Stokes shift, lifetime, and response to external stimuli (114,140-147). Adenosine analogs formycin (1), 2-aminopurine
ribonucleoside (2) and 2, 6-diaminopurine ribonucleoside (3), are amongst the first reported naturally occurring fluorescent nucleobases (figure 2.1) (148). These analogs have characteristic redshifted absorption (280 – 303 nm) and emission (340 – 370 nm) bands. A constitutional isomer of
adenine, 2-aminopurine is one of the most widely used fluorescent nucleoside because of its enhanced photo-physical properties, high quantum yield (Φ = 0.68) at physiological pH, low excitation
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energy, sensitivity to the micro-environment and ability to form WC-like base pairs with uridine
and thymidine.

Figure 2.1 Structures of naturally occurring fluorescent nucleosides.

2.2

Fluorescent Nucleoside Analogs: Expanded Nucleobases

Since the first report on fluorescence in nucleobases, a variety of fluorescent nucleosides,
derived from structural modification of 2-aminopurine, have been reported (149). Another remarkable fluorophore, 8-vinyl-deoxyadenosine (1, figure 2.2), was obtained by substituting the hydrogen at 8 position of adenine with a vinyl moiety (147,150,151). This modification produces remarkable photo-physical properties, like high quantum yield (Φ = 0.66) and pH insensitivity, making it a potential probe for exploring duplex structure and stability. Tor and co-workers were able
to design highly emissive nucleosides by incorporating a furan ring at the 8-position of purines (2
and 3) (152). They also developed a series of fluorescent thymidine and cytosine analogs by incorporating a furan/thiophene ring or fusing aromatic five-membered heterocyclic rings at the 5position of pyramidines (4 - 6) (153-157). Hirao and co-workers synthesized a series of fluorescent
purine analogs, for the expansion of the genetic alphabet by the unnatural base-pair systems, by
incorporating a thiophene or thiazole ring at the 6-position (7 - 9) (158-162). Such a substitution
results in red-shifted absorption bands (~355 nm) with strong emission in the visible region (~450
nm). These fluorophores have been helpful in site-specific RNA labeling.
Extended fluorescent nucleoside analogs can also be designed by tethering a fluorophore to
the natural nucleobase via flexible or rigid linkers. This method of connecting known
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chromophores to purines and pyramidines via electronically non-conjugating linkers spawn new
fluorophores/chromophores with unique photo-physical characteristics. In pursuit of basediscriminating fluorosides capable of detecting single nucleotide polymorphism (SNP), Saito and
co-workers designed pendant fluorophore-labeled deoxyuridine (10) and cytosine (11) analogs.
These nucleosides retain their hydrogen bonding face, have isolated absorption at ~335 nm and
intense emission at ~400 nm (Φ = ~0.2) (163).

Figure 2.2 Structures of fluorescent nucleoside analogs with expanded nucleobases.
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Seela et al. have meticulously investigated the photo-physical characteristics of adenosine
analogs by attaching functionalized alkenes and alkynes to the 7-position (12) (149,164). Unusual
2-substituted adenosine analogs (13), which displayed increased emission quantum efficiencies
upon incorporation in RNA, have also been reported (165). Xanthene-type fluorophores (14) were
investigated by Burgess and co-workers (166). The fluorophore is conjugated to the base via an
ethynyl linkage. An increase in extinction coefficient was observed upon extending the rigid linker
by a phenyl or phenyl-ethynyl moiety. The chemical structures for the discussed fluorophores 1 14 are shown in figure 2.2.
2.3

Fluorescent Nucleoside Analogs: Extended Nucleobases

Extended conjugation of natural nucleobases, resulting from the fusion of additional aromatic rings onto the purine/pyramidine core, also facilitates exciting and favorable photo-physical
properties, with high quantum efficiencies and emission in the visible range. In the early 1970s
Leonard and co-workers investigated the etheno- (1,) and benzo- (2) derivatives of adenine and
cytosine (figure 2.3) (167,168). These extended heterocycles display improved structural and optical properties.
These nucleosides have found unique fluorescence based applications in structural and
functional exploration of DNAs and RNAs (169,170). Godde et al. have reported fluorescent, napthosubstituted analogs of thymidine (3) and cytosine (4) (figure 2.3) (171,172). These fluorophores
have largely red-shifted absorption (360 – 370 nm) and emission (434 – 456 nm) bands with respect to the native nucleobases. With high fluorescence quantum yields (Φ = 0.82 for 3 and Φ = 0.62
for 4), these pH-responsive nucleosides and their derivatives have been successfully introduced
into oligonucleotides to get more insight about the double- and triple-stranded structures. Saito
and co-workers were able to gain attractive fluorescent properties by fusing benzo- and naphtharings to the nucleobases (5 – 8, figure 2.4)

(173-175). The cytidine analog 6 forms stable base

pairs: wobble base-pair with A and Watson-Crick base-pair with G. But this benzo-analog 6 has a
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lower quantum efficiency (Φ = 0.04) compared with its naphtho-analog 5 (Φ = 0.26) (174). The
adenosine (7) and inosine (8) analogs, with modest quantum yields (Φ = 0.12), act as acceptable
pyrimidine-discriminating fluorescent nucleosides.

Figure 2.3 Structures of fluorescent nucleoside analogs with extended nucleobases.

2.4

Fluorescent Hydrocarbons

Another simple procedure to generate fluorescent nucleosides is based on the replacement
of natural nucleobases with established fluorophores like polycyclic aromatic hydrocarbons. These
base analogs lack the Watson-Crick hydrogen bonding face, but facilitate selective excitation with
isolated absorption bands around and above 345 nm (141). Some selected examples are shown in
figure 2.4 with their respective names and quantum yields (114). Some of these nucleosides have
been beneficial in exploring the environment and dynamics of oligonucleotides (176-179).

Figure 2.4 Structures of fluorescent hydrocarbons. The respective quantum yields are reported in parenthesis.
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2.5

Metal Containing Fluorescent Nucleoside Analogs

Various metal containing emissive nucleosides have also been reported. Figure 2.5 shows
the chemical structures of some of these nucleosides. The electrochemistry and luminescent properties of RuII-complexes of 7-deazaadenine 2'-deoxyribonucleosides bearing bipyridine,
phenanthroline or terpyridine ligands (1, 2), linked to 7-position of deoxyadenosine via an acetylene or phenylene tether, was investigated by Hocek and co-workers (180). They also studied the
corresponding 2'-deoxyadenosine derivatives obtained by linking the spacer to the 8-position (3)
(181). The modified nucleosides exert significant cytostatic and antiviral effects. Tor an co-workers
have investigated the electrochemical and photo-physical properties nucleosides containing
[(bpy)2M(3-ethynyl-1,10-phenanthroline)]2+ (M = RuII, OsII) (4) metal center attached covalently to
the 5-position in 2'-deoxyuridine (182-185). They observed that the RuII-based nucleosides displayed stronger fluorescence (Φ = 0.137 at 629 nm) compared to the OsII-based nucleosides (Φ =
0.0003 at 749 nm). It was also found that upon incorporation in oligonucleotides, these nucleosides
cause minimal structural perturbation. These metal containing nucleosides have been used to synthesize a diverse variety of metal-containing nucleoside triphosphates which act as good substrates
for vent (exo-) and Pwo polymerases. The modified oligonucleotides thus obtained have found use
in detecting single nucleotide polymorphism via the luminescence generated by the fluorescent nucleoside (182-185).

Figure 2.5 Metal containing fluorescent nucleoside analogs.
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Unfortunately, these modifications are often bulky and usually result in colorless
fluorophores. Thus, such types of modifications are not ideal for probing the structure, function and
dynamics of nucleic acids. However, it is very challenging to design and discover minimallymodified nucleosides which are colored and exhibit significant fluorescence. Herein, we report the
first observation of fluorescence in a nucleoside with a single atom substitution. We have chemically synthesized 6-seleno-2'-deoxyguanosine (SedG) nucleoside by replacing oxygen atom at 6position with a selenium atom. This single atom modification not only imparts a strong yellow color
to the otherwise colorless 2'-deoxyguanosine (dG) nucleoside, but also makes it fluorescent under
physiological conditions. Since the label is small, it has significant advantages over classical fluorescent-labels with large functional groups. This new class of “atom-modified fluorescent labels” can
be very useful for luminescence based detection of nucleic acid and protein-nucleic acid complexes.
2.6

Material and Methods
2.6.1 Synthesis of 6-Seleno-2'-Deoxyguanosine

The synthesis of 6-seleno-2'-deoxyguanosine was achieved from commercially available
starting

material

N2-[2-(4-tert-butylphenoxy)acetyl]-5'-O-(4,4'-dimethoxytri-phenylmethyl)-2'-

deoxyguanosine (1) (scheme 2.1). Compound 2 was synthesized from compound 1 using published
procedure (2): a solution of 1 (500mg, 0.66 mmol), 4-dimethylaminopyridine (15 mg, 0.12 mmol,
DMAP) and triethylamine (0.18 mL, 1.32 mmol, 2 eq., TEA) was prepared in methylene chloride (2
mL, CH2Cl2) under argon. To this solution 2,4,6-(triisopropylbenzene)sulfonyl chloride (300 mg, 1
mmol, 1.5 eq., TIBS), dissolved in CH2Cl2 (1 mL), was added.The contents were stirred at room temperature for 15 min. The progress of the reaction was monitored by silica gel thin layer chromatography (TLC; 5% methanol in CH2Cl2). After the completion of reaction (as monitored by TLC), the
mixture was injected into sodium selenide (NCCH2CH2SeNa) solution. For preparing the sodium
selenide solution, di-(2-cyanoethyl) diselenide (700 mg, 2.64 mmol, 8 eq.) was dissolved in ethanol
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(15 mL) on an ice bath. A suspension of NaBH4 (150 mg) was prepared in ethanol (4 mL) and injected into the diselenide solution to furnish sodium selenide. The progress of selenium incorporation reaction was monitored by TLC (5% methanol in CH2Cl2). After the completion of reaction, water (10 mL) was added to the reaction flask. The solution was extracted with CH2Cl2 (3 x 20 mL) and
dried over anhydrous MgSO4. The solution was filtered and the solvent was evaporated under reduced pressure. The crude product was purified by a silica gel column equilibrated with CH2Cl2 and
eluted with a step-wise gradient of MeOH/CH2Cl2 mixtures (CH2Cl2, 1.0, 2.0, 3.0, 4.0% MeOH in
CH2Cl2, 200 mL each) to afford bright yellow N2-[2-(4-tert-butyl-phenoxy)acetyl]-6-(2cyanoethyl)seleno-5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxyguanosine (2, 460 mg, 80% yield
over two steps). The compound was used as such without any further characterization.
To deprotect the 5'-dimethoxytrityl (DMTr) group, N2-[2-(4-tert-butylphenoxy)acetyl]-6-(2cyanoethyl)seleno-5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-deoxyguanosine (2) (160 mg, 0.183
mmol) was dissolved in acetic acid (80%, 1 mL) and stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC (5% methanol in CH2Cl2). After the completion of reaction, the solution was neutralized with TEA and the solvent was evaporated under reduced pressure. The crude compound 3 was then purified by a silica gel column equilibrated with methylene
chloride and eluted with a step-wise gradient of methanol/ methylene chloride mixtures (CH2Cl2,
1.0, 2.0, 3.0, 4.0% MeOH in CH2Cl2, 200 mL each) to afford pale yellow N2-[2-(4-tert-butylphenoxy)acetyl]-6-(2-cyanoethyl)seleno-2'-deoxyguanosine (3, 95 mg, 91%). HRMS (ESI-TOF,):
molecular formula, C25H30N6O5Se; [M+H+]+: 575.1508 (calc. 575.1516), [M+Na+]+: 597.1351 (calc.
597.1335); 1H NMR (400 MHz, CD3SOCD3) δ: 1.25 (s, 9H, 3x CH3-tBu), 2.30-2.35 and 2.69-2.76 (2x
m, J1'-2'= 6.4 Hz, 2H, H-2'), 3.19 (t, J= 6.4 Hz, 2H, Se-CH2-CH2-CN), 3.53-3.62 (m, 2H, Se-CH2-CH2-CN),
3.53-3.62 (m, 2H) and 3.87-3.88 (br, 1H) (H-3' and H-5'), 4.43 (br, 1H, H-4'), 4.95 (s, 2H, CH2-O),
6.35 (t, J1'-2'= 6.4 Hz, 1H, H-1'), 6.86-6.88 (d, J = 8.64 Hz, 2H, CH-arom), 7.30-7.32 (d, J = 8.72 Hz, 2H,
CH-arom), 8.59 (s, 1H, H-8), 10.82 (s, 1H, NH);

13C

NMR (100 MHz, CD3SOCD3) δ: 18.37 and 18.89
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(Se-CH2-CH2-CN), 31.22 (CH3-tBu), 33.68 (C-tBu), 61.35 (C-5'),67.12 (CH2-O), 70.39 (C-3'), 83.31 (C4'), 87.85 (C-1'), 113.83 and 125.99 (CH-arom), 119.84 (CN), 130.25 (C-5), 142.51 (C-8), 143.03 and
157.24 (C-arom), 148.46 (C-6), 151.57 (C-4), 155.53 (C-2), 167.23 (C=O).

Scheme 2.1 Synthesis of 6-seleno-2'-deoxyguanosine (SedG).

Compound3 (10 mg, 0.017 mmol) was then treated with 0.05 M K2CO3 in methanol (4 mL;
pH = 10-11) at room temperature for 2 h to remove the cyanoethyl and (4-tert-butylphenoxy)acetyl protecting groups. The crude product was neutralized with HCl and purified by reverse phase high performance liquid chromatography (RP-HPLC). The 6-seleno-2'-deoxyguanosine
nucleoside was eluted at 355 nm, using a combination of two solvents at varying proportions: buffer A (2.5 mM TEAAc in water) and buffer B (2.5 mM TEAAc, 50% water and50% acetonitrile). The
fractions were lyophilized to afford bright yellow 6-seleno-2'-deoxyguanosine (4, 2.5 mg, 42%).
HRMS (ESI-TOF): molecular formula, C10H13N5O3Se; [M-H+]-: 330.0103 (calc. 330.0111); 1H NMR
(400 MHz, CD3OD) δ: 2.34-2.40and 2.62 -2.71(2x m, J1'-2'= 6.4 Hz, 2H, H-2'), 3.70-3.80 (quat. of d,
2H) and 3.98 (br, 1H) (H-3' and H-5'),4.51 (br, 1H, H-4'), 6.26 (t, J1'-2'= 6.4 Hz, 1H, H-1'), 8.23 (s, 1H,
H8); 13C NMR (100 MHz, CD3OD) δ: 41.38 (C-2'), 63.28 (C-5'), 72.67 (C-3'), 85.68 (C-4'), 89.39 (C-1'),
120.91 (C-5), 133.90 (C-8), 141.37 (C-4), 147.55 (C-2), 174.51 (C-6).
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2.6.2 Optical Studies of 6-Seleno-2'-Deoxyguanosine
All absorption and emission measurements were made in 10 mM sodium phosphate buffer.
UV-Vis spectra were recorded with respect to pure solvent/buffer reference. The pH of the buffer
was adjusted using HCl or NaOH solutions. For all the fluorescence measurements (unless mentioned) sample concentrations were fixed at 5 µM, and the excitation and emission slit widths were
fixed at 10 nm. The baseline was subtracted at all times. Both dG and SedGstock solutions were prepared in methanol for all measurements. The absorption and emission spectra were recorded at
every 1.0 pH unit (from pH 1-12) to study the effect of pH on dG and SedG (figures 2.9, 2.11 and
2.12). A pH titration curve was obtained for SedG by measuring the absorption every 0.1 pH unit
between pH 7 – 9 and every 0.5 – 1.0 pH unit between pH 4 – 7 and pH 9 – 12. Figure 2.10 shows a
plot of the titration data obtained.
2.6.3 HPLC Analysis and Purification of 6-Seleno-2'-Deoxyguanosine
The crude 6-seleno-2'-deoxyguanosine was purified and analyzed by reversed-phase high
performance liquid chromatography (RP-HPLC). The purification was performed on a Welchrom
C18-XB, 10 μm, 21.2*250 mm column using Shimadzu SPD-10A VP liquid chromatography with a
flow-rate of 6 mL/min [buffer A: 2.5 mM triethylammoniumacetate (TEAAc, pH 7.1) in water; buffer
B: 2.5 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 100 % buffer A to 100 %
buffer B in 15 min. The desired peak was collected and the buffer was removed by lyophilization.
All samples were analyzed on Welchrom C18-XB column (4.6*250 mm) and measured at a flow rate
of 1.0 mL/min and a linear gradient of 0 to 25% buffer B in 20 min [buffer A: 20 mM TEAAc (pH
7.1) in water; buffer B: 20 mM TEAAc (pH 7.1)in 50% acetonitrile].
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2.7

Results and Discussion
2.7.1 Synthetic Design

6-Seleno-2'-deoxyguanosine (4, scheme 2.1) was synthesized using N2-[2-(4-tertbutylphenoxy)acetyl]-5'-O-(4,4'-dimethoxytri-phenylmethyl)-2'-deoxyguanosine (1). The synthesis
of 2 has been previously reported (2). Compound 2 was detritylated using acid solution. The
cyanoethyl (CE) and (4-tert-butyl-phenoxy)-acetyl (t-BPAc) are labile protecting groups. These can
be deprotected under ultra-mild conditions (0.05 M K2CO3 in methanol). The de-protection, as discussed below, can also be monitored by UV-Vis due to the unique absorption profiles of compounds
3 and 4, resulting from the selenium-functionality (figure 2.7).
2.7.2 Absorption Properties of 6-Seleno-2'-Deoxyguanosine
Native 2'-deoxyguanosine (dG) has an absorption maximum at 254 nm (figure 2.6). Introduction of selenium yields an interesting absorption profile to the nucleoside. The absorption spectrum

of

N2-[2-(4-tert-butyl-phenoxy)acetyl]-6-(2-cyanoethyl)seleno-2'-deoxy-guanosine

(N2-

tBPAc-6-CE-Se-dG, 3) shows discreet bands at 256 nm and 308 nm (figure 2.6) in aqueous solution.
When the protecting groups are completely removed, the resulting SedG (4) shows an isolated absorption maximum at 357 nm and is bright yellow in color (inset: figure 2.6). Thus, a single atom
replacement not only imparts a strong color to the otherwise colorless nucleoside, but also results
in over 100 nm red-shift in the UV absorption. This observation was also confirmed by the HPLC
analysis comparison of commercial dG with synthesized SedG at 260 nm and 360 nm (figure 2.7).
SedG

absorbs at both 260 nm (slightly) and 360 nm (strongly), whereas native dG has no absorb-

ance at 360 nm.

21

Figure 2.6 Absorption spectra of dG (—), N2-tBPAc-6-CE-Se-dG (—), and SedG (—) in water at 25 ˚C. Inset: SedG (left): yellow; dG (right): colorless.

Figure 2.7 RP-HPLC analysis of dG and SedG [monitored at 260 nm (red) and 360 nm (black)]; (a) and (b) commercial dG
(retention time: 13.9 min); (c) and (d) synthesized SedG (retention time: 14.8 min); (e) and (f) co-injection of commercial
dG and synthesized SedG (retention times: 13.9 and 14.8 min, respectively).

X-ray crystallographic analysis and theoretical calculations, have confirmed the existence of
6-thioguanine in different tautomeric forms (186-188). Tautomerism in 6-selenoguanine has also
been investigated using high-level ab initio calculations (189). Of the different tautomers possible,
the 6-selenol form was found to be the most stable in gas phase, whereas the 6-selenone form was
predicted to be the most stable in aqueous solution (figure 2.8). The introduction of seleniumfunctionality also influences the pKa of N-1 imino proton in guanosine; deprotonation generates the
more stable 6-selenolic form (189,190). Interestingly, during the pKa measurements on SedG, we
observed that the 6-selenolic form has a distinct UV-absorption profile (figure 2.9 A). The protona-
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tion-deprotonation of SedG and dG (for comparison) was monitored by UV spectrophotometry in
solutions with pH values ranging from 1 to 12 (figure 2.9 A and B respectively). In basic solutions,
the absorption maximum of

SedG

shifts to ~330 nm, whereas, the absorption maximum is red-

shifted to ~357 nm under neutral and acidic conditions. Under highly acidic conditions (pH 1), the
nucleobase is completely protonated and absorbs around 367 nm (figure 2.9 A). Taking advantage
of the strong dependence of absorption on solution pH, we calculated the pKa of SedG by recording
the UV-Vis spectra at different pH values. The pKa (7.57 ± 0.02) of SedG was obtained from the fitted
titration plot (figure 2.10).

Figure 2.8 Tautomers of 6-seleno-2'-deoxyguanosine, SedG.

Figure 2.9 UV-Vis spectra: absorption profiles of (A) SedG and (B) dG, as a function of pH.
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Figure 2.10 pKa titration plot: pH versus wavelength (nm) plot for SedG; the fitted curve yields the pKa value 7.57 (± 0.02).

2.7.3 Emission behavior of 6-Seleno-2'-Deoxyguanosine: pH Effect
Guanine and its nucleosides/nucleotides are known to fluoresce in extreme pH conditions
(pH ~1) (136,139). The low pH luminescence is dictated by the electron distribution at the guanine
base in such conditions. Thus, it is meaningful to investigate the impact of introducing seleniumfunctionality into the guanosine base; especially the fluorescence of SedG as a function of pH since
the electron-rich Se atom alters the dG electron distribution. Therefore, we measured the fluorescence of SedG in solutions with pH values ranging from 1 to 12 (figure 2.11). For the direct comparison, fluorescence from dG was also measured (figure 2.12). The pH-dependent fluorescence profile
obtained for dG is consistent with data presented in some early reports (136,139). With an excitation wavelength of 258 nm (same as the absorption maximum), dG has maximum fluorescence
emission at 395 nm. However, the pH dependant emission from SedG narrates a different story: with
an excitation wavelength of 305 nm (which is not the same as the absorption maximum of ~ 360
nm) SedG has maximum fluorescence emission at 395 nm. It is probably due to the fluorescence
quenching by solvent (water) molecules that no emission is observed on excitation of SedG at 360
nm. Unlike dG, SedG is practically non-emissive under strong acid conditions (pH 1-2). SedG is fluorescent in solutions with other pH, with maximum emission at pH 6.0. Our experiments also indi-
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cate that SedG is fluorescent under physiological pH 7.4. The concentration-dependent fluorescence
profiles, at pH 6 and pH 7.4, are presented in figures 2.13 and figure 2.14, respectively.

Figure 2.11 Fluorescence spectra of SedG in aqueous solutions with pH 1-12: (A) Excitation spectra of SedG as a function of
pH at 25 ˚C; the emission wavelength was 390 nm. (B) Emission spectra of SedG as a function of pH at 25 ˚C, with excitation at 305 nm.

Figure 2.12 Fluorescence spectra of dG in aqueous solutions with pH 1-12: (A) Excitation spectra of dG as a function of pH
at 25 ˚C; the emission wavelength was 395 nm. (B) Emission spectra of dGas a function of pH at 25 ˚C, with excitation at
258 nm.
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Figure 2.13 Concentration-dependent fluorescence spectra of SedG at pH 6: (A) Excitation spectra of SedG at pH 6 and 25
˚C; the emission wavelength was 390 nm. (B) Emission spectra of SedG at pH 6 and 25 ˚C; the excitation wavelength was
305 nm.

Figure 2.14 Concentration-dependent fluorescence spectra of SedG at pH 7.4: (A) Excitation spectra of SedG at pH 7.4 and
25 ˚C; the emission wavelength was 390 nm. (B) Emission spectra of SedG at pH 7.4 and 25 ˚C; the excitation wavelength
was 305 nm.

2.7.4 Emission behavior of 6-Seleno-2'-Deoxyguanosine: Solvent Effect
Solvent polarity is a significant parameter when considering any environmental effect on
the absorption and emission spectra (147,191-193). Thus, we measured the UV-Vis absorption of
SedG

in different solvents and observed that SedG nucleoside exhibits interesting solvatochromicity

(figure 2.15). In general, the UV-absorption maximum is red-shifted to approximately 370 nm in
polar solvents. A detailed analysis on the fluorescence of SedG, in solvents with different polarities,
was also performed (figure 2.16). Excitingly, SedG is noticeably emissive in iso-propanol and has
little or no fluorescence in other solvents used in this study, which suggests that the solvent polarity
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can significantly affect the emission profile. Such polarity-dependent emission is probably due to
ground state interactions between the nucleoside and the solvent molecules. The excitation spectra
of SedG in different solvents were monitored at 405 nm. We found that the fluorescence excitation
maxima were slightly red-shifted to 320 nm in the organic solvents. Concentration-dependent fluorescence profiles for SedG in isopropanol (figure 2.17) and ethanol (figure 2.18) were also obtained.

Figure 2.15 UV-Vis spectra: absorption profile of SedG in different solvents at 25 ˚C.

Figure 2.16 Fluorescence spectra of SedG in different solvents: (A) Excitation spectra of SedG in different solvents at 25 ˚C;
the emission wavelength was 405 nm. (B) Emission spectra of SedG in different solvents at 25 ˚C; the excitation wavelength was 320 nm.
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Figure 2.17 Concentration-dependent fluorescence spectra of SedG in iso-propanol: (A) Excitation spectra of SedG at 25 ˚C;
the emission wavelength was 395 nm. (B) Emission spectra of SedG at 25 ˚C; the excitation wavelength was 320 nm.

Figure 2.18 Concentration-dependent fluorescence spectra of SedG in ethanol: (A) Excitation spectra of SedG at 25 ˚C; the
emission wavelength was 395 nm. (B) Emission spectra of SedG at 25 ˚C; the excitation wavelength was 320 nm.

2.8

Conclusions

We have developed a simple strategy for synthesizing 6-seleno-2′-deoxyguanosine (SedG).
Although structurally similar to 2′-deoxyguanosine (dG), SedG exhibits distinctive optical properties.
Unlike dG, the single atom modified SedG is a bright yellow solid and is fluorescent under physiological conditions. To our knowledge, this is the first observation of a fluorescent nucleoside obtained
by single-atom alteration. We also found that the absorption and emission of SedG are sensitive to
pH and solvent polarity. Thus, the Se-modified nucleoside has great potential as a useful visual and
fluorescent probe for to investigate protein-nucleic acid interactions and further contribute to mo-
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lecular understanding of the protein dynamics. In particular, this fluorescent Se-nucleoside would
be very useful in studying the structure and dynamics of trans-membrane transporter proteins for
understanding the mechanisms of active transportation in biological membranes at the molecular
level and identifying the molecular basis of the action of drugs that target the transporter proteins.
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CHEMICAL SYNTHESIS AND FLUORESCENCE STUDY OF 6-SELENO-2'-

DEOXYGUANOSINE DERIVATIZED OLIGODEOXYRIBONUCLEOTIDES
3.1 Synthetic Oligodeoxyribonucleotides
The rational design of drugs and therapeutic agents has become more plausible with our increasing understanding of biochemistry and molecular and cellular biology. Chemically modified
nucleic acids, with their diverse functionalities, have drawn widespread attention from multidisciplinary research teams. Ample growth has occurred in developing optimized and automated methods for the preparation of modified nucleic acids, which serve as significant tools in fundamental
research as structure-and-function probes, chemical probes, and mechanistic probes. Synthetic oligonucleotides have been useful probes in exploring the biochemical processes and pathways. Availability of diverse variety of modified nucleosides, development of functionalized phosphoramidites,
and proficient methods for the solid-phase as well as enzymatic synthesis, have augmented the utility of such oligonucleotides. Various reports have underscored the synthesis and application of synthesis oligonucleotides with modifications in the sugar, purine/pyramidine heterocyclic base, and
the phosphodiester backbone (15,30,167,194-201).
Selenium-modified nucleic acids (SeNAs) are valuable derivatives for crystallographic phase determination (49,55,63,66,202). SeNA are promising candidate for crystallographic phasing and other biological applications. Huang and coworkers have developed diverse building units for the incorporation of 2-Se-thymidine (Se2T) (57), 4-Se-thymidine (Se4T) (1), 6-Se-guanosine (Se6G) (2,50),
and 2-Se-uridine (Se2U)(51,53) into DNA and RNA by solid-phase synthesis. Crystallographic studies with the corresponding selenium-modified oligonucleotides demonstrate improved stability and
binding affinity, with insignificant structural perturbation. Structurally these are very similar to the
native oligonucleotides. Interestingly, the atom-specific replacement of oxygen with selenium in the
nucleobases also imparts a bright yellow color to the otherwise colorless nucleoside (hence, the
corresponding nucleotide and oligonucleotide). For instance, relative to the native dG (UV λ max= 254
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nm, ε = 1.22 x 104M-1cm-1), the absorption maximum of Se6dG (UV λmax= 360 nm, ε = 2.3 x 104M-1cm1)

is red-shifted by 100 nm, resulting in yellow DNA(2). This large shift in the absorption maximum

is likely due to the greater delocalization of selenium electrons, thereby lowering the excitation energy of the nucleotide.
Herein we report the solid-phase synthesis of short oligodeoxyribonucleotides (trimers) functionalized with 6-seleno-deoxyguanosine nucleoside. The purified and characterized oligos were
analyzed for their optical behavior.
3.2 Material and Methods
3.2.1 Solid-Phase Synthesis of 6-Seleno-2'-Deoxyguanosine Derivatized
Oligodeoxyribonucleotides
Synthesis

of

SedG

phosphoramidite:

N2-[2-(4-tert-butyl-phenoxy)acetyl]-6-(2-

cyanoethyl)seleno-2'-deoxyguanosine phosphoramidite (5, scheme 3.1) was synthesized from N2[2-(4-tert-butyl-phenoxy)acetyl]-6-(2-cyanoethyl)seleno-5'-O-(4,4'-dimethoxytriphenylmethyl)-2'deoxyguanosine (2, scheme 2.1) using a previously published procedure (2): Compound 2(250 mg,
0.29 mmol) and 5-(benzylthio)-1H-tetrazole (BTT, 27 mg, 0.15 mmol) were weighed out in a 15 mL
flask and dried overnighton a high vacuum. The compounds were then dissolved in anhydrous
methylene

chloride

(1

mL)

under

argon.

After

this

2-cyanoethyl

N,N,N,N-

tetraisopropylphosphorodiamidite (phosphoramidite, 103 mg, 0.34 mmol, 1.2 eq.) was injected into
the reaction flask and the solution was allowed to stir at room temperature for 30 min under argon.
The progress of the reaction was monitored by recording TLC (30% ethyl acetate in CH 2Cl2): a mixture of two diastereomers is obtained. After the complete consumption of starting compound (as
indicated by TLC) the reaction was quenched with saturated sodium bicarbonate (NaHCO3, 3 mL),
stirred for 5 min. and extracted with CH2Cl2 (3 x 5 mL). The combined organic layer was dried over
anhy. MgSO4, filtered and the solvent was evaporated under reduced pressure. The crude product
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(mixture of two diastereomers) was purified on a silica gel column equilibriated with CH2Cl. The
product was eluted with (30% ethyl acetate in CH2Cl2). The product obtained from the column was
further dissolved in CH2Cl2 (1 mL) and precipitated from pentane (200 mL) as a pale green solid
(230 mg, 75 % yield).

Scheme 3.1 Synthesis of 6-seleno-2'-deoxyguanosine modified oligonucleotides, 6.

Synthesis of SedG Oligodeoxyribonucleotides (6): an automated Applied BioSystem 394 DNA
Synthesizer (Applied Biosystems, Foster City, CA) was used to synthesize all the modified
oligodeoxyribonucleotides (ODNs), employing standard β-cyanoethylphosphoramidite chemistry
(1 μmol scale). Only ultra-mild native nucleoside phosphoramidite reagents (Glen Research) were
used in the synthesis. Oligonucleotides were synthesized in DMTr-on mode. The synthesized ODNs
were cleaved from the beads and simultaneously deprotected (cyanoethyl and (4-tert-butylphenoxy)-acetyl protecting droups) by treating with 0.05 M K2CO3/methanol solution at room temperature for 12 h. The solution was then neutralized with 2 M TEAAc buffer (pH 7.1) and purified
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by RP-HPLC. For 5'-DMTr deprotection, the lyophilized ODNs were acidified to pH 5 using acetic
acid and heated at 45 ⁰C for 1 h. After complete detritylation (monitored by analysis on HPLC), the
samples were neutralized with 2 M TEAAc buffer (pH 7.1) and re-purified by RP-HPLC. The samples
were then deslated using Sep-Pak C18 3 cc Vac column.
3.2.2 HPLC Analysis and Purification
The DMTr-on modified ODNs were eluted at 260 nm, with a flow-rate of 6 mL/min [buffer
A: 10 mM TEAAc (pH 7.1) in water; buffer B: 10 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 10 % buffer B to 100 % buffer B in 15 min. The desired peaks were collected and
the buffer was removed by lyophilization. All the samples were analyzed on Welchrom C18-XB column (4.6*250 mm) at 260 nm and 360 nm, and measured at a flow rate of 1.0 mL/min and a linear
gradient of 5 % to 60 % buffer B in 8 min, reaching 100 % buffer B in 12 min [buffer A: 20 mM
TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH 7.1)in 50% acetonitrile]. The DMTr-off modified ODNs were also eluted at 260 nm, with a flow-rate of 6 mL/min [buffer A: 10 mM TEAAc (pH
7.1) in water; buffer B: 10 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 5 %
buffer B to 70 % buffer B in 15 min., reaching 100 % buffer B in 20 min. The desired peaks were
collected and the buffer was removed by lyophilization. All the samples were analyzed on
Welchrom C18-XB column (4.6*250 mm) at 260 nm and 360 nm, and measured at a flow rate of 1.0
mL/min and a linear gradient of 5 % to 40 % buffer B in 15 min, reaching 100 % buffer B in 17 min
[buffer A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH 7.1) in 50% acetonitrile].
3.2.3 Desalting Using Sep-Pak C18 Vac Column
The DMTr-off ODNs were deslated using Sep-Pak C18 3 cc Vac column: the column was
equilibrated by eluting pure acetonitrile (1 mL), followed by water (1 mL) and TEAAc buffer (2 M,
pH 7.1, 1 mL)). The detritylated sample (dissolved in 0.5 mL water) was loaded on the column. The
sample was desalted by washing with water (3 X 1 mL) and eluting desalted ODNs with 40 % ace-
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tonitrile in water (0.6 mL). All the fractions were analyzed by UV-Vis. The product containing fraction was lyophilized to dryness. The samples were then quantified by UV-Vis analysis and used for
fluorescence measurements.
3.2.3 Optical Analysis of SedG ODNs
All absorption measurements were made in de-ionized water (unless mentioned). The
emission measurements were made in 10 mM sodium phosphate buffer (of specified pH). The pH of
the buffer was adjusted using HCl or NaOH solutions. For all the fluorescence measurements (unless mentioned) sample concentrations were fixed at 10 µM, and the excitation and emission slit
widths were fixed at 10 nm. The baseline was subtracted at all times. Thestock solutions were prepared in de-ionized water for all measurements.
3.3

Results and Discussion
3.3.1 Synthetic Design

A list of 6Se-dG-modified oligodeoxyribonucleotides used in this study is presented in table
3.1. The SedG derivatized ODNs were synthesized using ultramild phosphoramidites. Strong basic
conditions, like ammonia treatment, for the deprotection of the nucleobase cause de-selenization of
the modified

SedG

nucleobase. Thus, ultramild amine protecting group [(4-tert-butyl-

phenoxy)acetyl] was used. These ultramild protecting groups can be removed under ultramild
deprotection conditions, i.e. 0.05 M K2CO3 in methanol (r.t., 12 h). The ODNs could be synthesized
either in DMTr-on or DMTr-off mode.
Table 3.1Sequences of SedG-ODNs used for fluorescence measurements.

1. d-(ASeGA)
2. d-(GSeGG)
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3.3.2 UV-Vis Analysis
The DMTr-off and desalted modified ODNs were analyzed by UV-Vis spectrophotometry. All
the SedG-derivatized ODNs are yellow in color and exhibit two discreet absorption bands: one at ~
260 nm corresponding to absorption by native nucleobases and, other at 360 nm arising from the
selenium modification in the nucleobase. The

SedG

derivatized ODNs have a strong tendency to

dimerize. The dimer has a blue-shifted absorption maximum at ~330 nm. Thus, a broad absorption
band in UV-Vis spectrum, stretching from 330-360 nm, indicates the presence of both –monomer
and dimer species in the sample solution. Figure 3.1 presents the UV-Vis analysis of the synthesized
and purified ODNs. The UV-Vis analysis of ASeGA in pH 6 and pH 9 is also shown. It clearly demonstrates conversion to a dimeric species, with absorption ~ 330 nm, at pH 9 whereas at pH 6 it still
has a strong absorption at 360 nm, indicating the presence of a 6Se-dG monomer. The extinction
coefficient for SedG at 260 nm (5.3 x 103 M-1cm-1) and 360 nm (2.3 x 104 M-1cm-1) have been previously reported (2). The extinction coefficient for SedG at 260 nm was used to calculate the quantity
of the ODNs obtained.

Figure 3.1 Absorption spectra of SedG-modified oligodeoxyribonucleotides.
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3.3.3 HPLC Analysis
The HPLC analysis of the synthesized and purified SedG-derivatized ODNs further supported
the dimerization of SedG under experimental conditions. The RP-HPLC profiles for ASeGA and GSeGG
trimers, at wavelengths 260 nm, 330 nm and 360 nm, are shown in figure 3.2. The ASeGA trimer, has
two peaks with retention times of 11.9 min and 13.7 min (figure 3.2 A). The peak at 11.9 min is
from the trimer with SedG in the form of a monomer, as the signal corresponding to 330 nm is very
weak and 360 nm is strong. The peak with a retention time of 13.7 min is from the trimer where
SedG

has already dimerized as the signal corresponding to 330 nm is stronger and 360 nm is weak-

er. A similar pattern is also observed for GSeGG trimer (figure 3.2 B). The retention time for the peak
corresponding to SedG monomer is 10.5 min whereas the peak illustrating dimerized SedG has a retention time of 13.1 min.

Figure 3.2 RP-HPLC analysis of ASeGA and GSeGG trimers [monitored at 260 nm (black), 330 nm (green) and 360 nm
(red)]; A. Purified ASeGA sample (retention time: 11.9 min for SedG monomer and 13.7 min for SedG dimer); B. Purified
GSeGG sample (retention time: 10.5 min for SedG monomer and 13.1 min for SedG dimer).

3.3.4 Fluorescence Analysis
The emission behavior of ASeGA and GSeGG trimers was analyzed under physiological pH
(7.4). The samples were excited at different wavelengths to get different emission profiles. But it
appears that the fluorescence of SedG is quenched in these ODNs. The strongest emission was observed with excitation at 260 nm and 305 nm (figure 3.3). The emission from ASeGA is stronger
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compared to emission from GSeGG trimer. This indicates that the neighboring nucleobases have a
significant effect on the fluorescence arising from SedG.

Figure 3.3Emission spectra of ASeGA and GSeGG trimers in solution with pH 7.4: (A) excitation at 260 nm; (B) excitation at
305 nm.

3.4
We

Conclusions
have

demonstrated

that

6-seleno-2′-deoxyguanosine

derivatized

oligodeoxyribonucleotides can be successfully synthesized using the strategy we developed recently (2). The synthesized ODNs are yellow in color and structurally similar to the native ODNs with
only a single atom modification. Like the SedG nucleoside, SedG-modified ODNs also have interesting
absorption profile with two discreet absorption bands at ~ 260 nm and 360 nm. Unlike the SedG nucleoside, the fluorescence from

SedG-modified

ODNs appears to be significantly quenched. The

emission from SedG-modified ODNs is also dependant on the neighboring bases of SedG. But being
strongly yellow in color, the Se-derivatized ODNs have great potential as a useful visual probe for
nucleic acid transportation, diagnosis and dynamics.
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SYNTHESIS OF 6-SELENO-2'-DEOXYGUANOSINE-5'-TRIPHOSPHATE AS A BIO-

CHEMICAL PROBE
4.1 Synthetic Nucleotides
Nucleotides play crucial role in several metabolic processes like DNA polymerization, RNA
transcription and protein synthesis. Nucleotides are powerful building units for creating functional
molecules with novel properties. They can be easily modeled and functionalized at various positions with diverse functional groups. The basic structure of a nucleotide consists of three components: a base, a sugar and a phosphate group. All these three components have various active sites
which were and still are prime targets for chemists for various modifications. Various modifications
have helped scientists to have an in-depth understanding about nucleic acid structures, functions
and dynamics like the factors responsible for stronger Watson-Crick base pairing, helical backbone,
thermodynamic stability of DNA/RNA duplexes, efficient cross-pairing and improved binding and
catalysis (203-209). Nucleoside triphosphates serve as direct precursors for chemical and enzymatic synthesis of modified (unnatural) nucleic acids. Synthetic nucleotides also serve as efficient substrates to a variety of DNA and RNA polymerases(210-215) and have been helpful in probing the
ability and specificity of DNA polymerases (216) and binding and catalytic ac. The modification of
nucleic acids presents enormous opportunities for tailoring the properties and functions of these
biomolecules, escalating their potential in biochemical and biomedical applications (10-20).
4.2 Selenium Functionalized Nucleotides
Selenium derivatization of nucleic acids generates modified biopolymers with novel properties. In search of bioactive compounds, a variety of modified nucleosides and nucleotides, with selenium functionalization at different positions in the nucleobase, sugar, and phosphate group, have
been

successfully

achieved

by

Huang’s

research

group,

along

with

other

groups

(46,47,49,50,53,55,57-66). Selenium-derivatized nucleic acids entail unique structural and func-
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tional features like, stability and compatibility with chemical and enzymatic synthesis, which make
them strong contenders for biochemical and biophysical research. The synthesis of nucleoside triphosphate analogues with selenium at the non-bridging α-position of phosphate has been successfully demonstrated by Huang and co-workers (217,218). Owing to the chirality of the selenophosphate, the synthesis results in the formation of RP and SP diastereomers. As a typical example,
both the diastereomers obtained from the synthesis of thymidine 5'-(α-P-seleno)-triphosphate (αSe-TTP) were subjected to enzymatic synthesis of PSe-DNAs (217). It was observed that the DNA
polymerase is capable of recognizing both the diastereomers to the same capacity as the natural
TTP. The SP and RP diastereomers of the Se-derivatized nucleotides are instrumental for the fundamental understanding of the structure and biophysical chemistry of the polymerases, nucleases,
kinases and phosphatases. Synthesis of a yellow 4-Se-thymidine-5'-triphosphate (SeTTP) from the 4Se-thymidine nucleoside was also successfully achieved by the Huang group (3). This modified
SeTTP

acts as a good substrate for DNA polymerase and is recognized with virtually the same effi-

ciency as the native TTP. The enzymatic incorporation of SeTTP also results in yellow DNA. These
colored Se-DNAs could serve as unique visual probes for enzymatic assays. Thus, the nucleotides
and nucleic acids obtained by atom-specific substitution of oxygen with selenium, could serve as
useful biophysical, structural, and mechanistic probes (1,2,49-51,55,57,66).
4.3 Fluorescent Nucleotide Substrates
Fluorescent nucleotides, with well analyzed fluorescence behavior and which are good substrates to the polymerases, can be used to a great advantage in a variety of studies including the dynamics and mechanism of substrate binding and transformation. With such potential significance,
considerable efforts have been made towards the development of fluorescent nucleotides. Several
fluorescent nucleotide analogs have been reported in literature (114,219-227). These modified
fluorophores also find use in diverse applications as molecular probes and nucleic acid reporters.
But most of the reported fluorescent nucleotides have severe limitations: some are neither sub-
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strates nor inhibitors of polymerases (219,228), some have low quantum yields, while some are
structurally perturbing or incompatible. Most of the reported fluorescent nucleotides are colorless,
thus making them unsuitable for probing the structure and dynamics of nucleic acids. On the other
hand, selenium derivatization of the nucleobase imparts a strong yellow color to the otherwise colorless nucleotides and nucleic acids, resulting in strongly colored DNAs and RNAs. Incorporation of
a single Se atom in the nucleobases can cause over a 100 nm red-shift in the absorption maximum
of the nucleobases (1-3). This distinctive property is very useful in nucleic acid-based detection and
visualization. With their unique spectroscopic properties, the Se-DNAs have great potential in detection, visualization, and profiling of nucleic acids and their complexes. Herein, we report the first
chemical synthesis of a fluorescent nucleotide 6-Se-2'-deoxyguanosine-5'-triphosphate (SedGTP)
obtained by single atom replacement of C6 oxygen with selenium. With discrete optical properties,
the selenium-modified triphosphate is bright yellow and measurably fluorescent under physiological conditions. It is a good substrate for DNA polymerase and results in nuclease-resistant yellow
DNA. All these unique features make SedGTP a strong candidate for an effective nucleic acid visualization probe.
4.4 Material and Methods
4.4.1 Synthesis of 6-Seleno-2'-Deoxyguanosine-5'-Triphosphate
N2-tBPAc-6-CE-Se-dG (3, scheme 2.1, 10 mg, 0.0178 mmol) was weighed in a 10 mL r.b.
flask and dried overnight under vacuum. 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (7.2 mg,
2 eq.) was dried in a flask for 10 min. Tri-n-butylammonium pyrophosphate (25 mg, 3 eq.) was
dried overnight in a separate flask, under high vacuum. The pyrophosphate was dissolved in DMF
(0.3 mL) with additional TBA (0.1 mL) and transferred into the flask containing 2-chloro-4H-1,3,2benzodioxa-phosphorin-4-one, dissolved in DMF (0.2 mL). The mixture was flushed with argon and
allowed to stir at room temperature. After 30 min. the mixture was transferred into the flask con-
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taining vacuum dried compound 3 dissolved in dioxane (0.2 mL) and DMF (0.1 mL). The combined
contents were allowed to stir at room temperature for 4 h to yield the cyclic phosphite intermediate
8 (scheme 4.1). The cyclic-phosphite 8 was then oxidized by adding iodine solution (0.02%
I2/THF/Pyridine/H2O, 1 mL). The mixture was stirred for 1 h and then hydrolyzed with water (3
mL) and allowed to stir at room temperature for 4 h to ensure complete hydrolysis. The sample was
precipitated using NaCl (0.3 M)/ ethanol (3 volumes). The precipitate was analyzed by recording a
TLC (5:3:2 of iso-PrOH:NH3.H2O:H2O). The crude N2-[2-(4-tert-butyl-phenoxy)acetyl]-6-(2cyanoethyl)seleno-2'-deoxyguanosine-5'-triphosphate, N2-tBPAc-6-CE-Se-dGTP, 9 was then purified by reverse phase HPLC. HRMS (ESI-TOF): molecular formula, C25H33N6O14P3Se; [M-H+]-:
813.0338 (calc. 813.0360); 1H NMR (400 MHz, D2O) δ: 1.19(s, 9H, 3x CH3-tBu), 2.58-2.63 and 2.812.88 (2x m,2H, H-2'), 3.11 (t,J = 6.76 and 6.92 Hz,2H, Se-CH2-CH2-CN), 3.51(t,J = 6.36 and 6.88 Hz,2H,
Se-CH2-CH2-CN), 4.17-4.23 (m, 2H) and4.30 (br, 1H)(H-3' and H-5'),6.54 (t,J1'-2'= 6.66 Hz,1H, H1'),6.89-6.92 (d, J = 8.68 Hz, 2H, CH-arom),7.30-7.33 (d, J = 8.64 Hz, 2H, CH-arom),8.59 (s, 1H, H-8);
13C

NMR(100 MHz, D2O)δ: 19.46 and 19.85 (Se-CH2-CH2-CN),31.52 (CH3-tBu),34.31 (C-tBu), 39. 85

(C-2'),63.33 (C-5'),66.32 (CH2-O),71.85 (C-3'),84.47 (C-4'),86.81 (C-1'), 114.94 and 127.36 (CHarom), 121.46 (CN), 131.06 (C-5),143.57 (C-8), 146.08 and 159.30 (C-arom),148.88 (C-6),151.91
(C-4), 155.37 (C-2), 170.55 (C=O); 31P NMR (162 MHz, D2O) δ: -22.56 (t, Jβ = 19.88 and 19.94 Hz, 1P,
P-β), -10.98 (d, Jα = 19.76 Hz, 1P, P-α), -9.43 (d, Jγ = 19.70 Hz, 1P, P-γ).
HPLC purified N2-tBPAc-6-CE-Se-dGTP (9)was treated with 0.05 M K2CO3 (4:1 = MeOH: H2O;
5 mL) at room temperature for 12 h, to remove the 2-cyanoethyl and (4-tert-butyl-phenoxy)-acetyl
protecting groups. The pure 6-seleno-2'-deoxyguanosine-5'-triphosphate (SedGTP, 10) was recovered as a bright yellow solid by NaCl (0.3 M)/ ethanol (3 volumes) precipitation. The precipitates
were analyzed by UV-Vis, HPLC and TLC (5:3:2 of iso-PrOH: NH3.H2O: H2O). No further purification
was carried out. HR-MS (ESI-TOF): molecular formula, C10H16N5O12P3Se; [M-H+]-: 569.9087 (calc.
569.9101); 1H NMR (400 MHz, D2O) δ: 2.52-2.56 and 2.83 -2.29 (2x m, 2H, H-2'), 4.24-4.29 (m, 3H,
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H-3'and H-5'), 6.36 (t, 1H, J1'-2'= 6.68 and 6.8 Hz, H-1'), 8.35 (s, 1H, H8); 13C NMR (100 MHz, CD3OD)
δ: 35.98 (C-2'), 62.96 (C-5'), 68.45 (C-3'), 83.35 (C-4'), 83.41 (C-1'), 138.75 (C-5), 139.51 (C-8),
148.74 (C-4), 157.37 (C-2);31P NMR (162 MHz, D2O) δ: -21.60 (t, Jβ = 19.05 and 20.07 Hz, 1P, P-β), 10.87 (d, Jα = 18.95 Hz, 1P, P-α), -6.22 (d, Jγ = 19.67 Hz, 1P, P-γ).
4.4.2 HPLC Analysis and Purification
The crude N2-tBPAc-6-CE-Se-dGTP (9)was purified and analyzed by reversed-phase high
performance liquid chromatography (RP-HPLC). The N2-tBPAc-6CE-Se-dGTP was eluted at 305 nm,
with a flow-rate of 6 mL/min [buffer A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc
(pH7.1) in 50% acetonitrile] and a linear gradient from 5 % buffer B to 100 % buffer B in 30 min.
The desired peak was collected and the buffer was removed by lyophilization. All samples were analyzed on Welchrom C18-XB column (4.6*250 mm) and measured at a flow rate of 1.0 mL/min and
a linear gradient of 0 to 40 % buffer B in 25 min [buffer A: 20 mM TEAAc (pH 7.1) in water; buffer
B: 20 mM TEAAc (pH 7.1)in 50% acetonitrile]. The yellow precipitates of SedGTP (7) were analyzed
at 260 and 360 nm wavelengths with a flow rate of 1.0 mL/min and a linear gradient of 0 to 25 %
buffer B in 20 min (figure 4.2).
4.4.3 UV-Vis Absorption and Fluorescence Study
All absorption spectra were recorded in de-ionized water (figures 4.1). All the emission
measurements were made in 10 mM sodium phosphate buffer (figures 4.3and 4.4). The pH of the
buffer was adjusted using HCl or NaOH solutions. For all the fluorescence measurements (unless
mentioned) sample concentrations were fixed at 5 µM, and the excitation and emission slit widths
were fixed at 15 nm. The baseline was subtracted at all times. The SedGTPstock solution was prepared in water for all measurements.
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4.4.4 Synthesis of Oligonucleotides
The DNA promoter (P) and template (T) sequences (table 4.1) were synthesized on an automated Applied BioSystem 394 DNA Synthesizer (Applied Biosystems, Foster City, CA) employing
standard β-cyanoethylphosphoramidite chemistry (1 μmol scale). Oligonucleotides were synthesized in DMTr-off mode, with average coupling efficiency greater than 99%. The oligonucleotides
were de-protected in concentrated NH4OH (55 °C, 16 h), and purified by 19% denaturing polyacrylamide gel electrophoresis. The gel was visualized under UV light, crushed and soaked in water.
The oligonucleotides were recovered from water solution by NaCl (0.3 M)/ ethanol (3 volumes)
precipitation. Oligonucleotides were quantified by UV-Vis absorbance at 260 nm using standard
molar extinction coefficients and characterized by MALDI-TOF MS.
4.4.5 Enzymatic Incorporation Studies
DNA primers were labeled at the 5'-terminus by incubating in the presence of γ-[32P]-ATP
(Perkin Elmer, Boston, MA) and T4 polynucleotide kinase (New England Biolabs, Beverly, MA) for 1
h at 37 °C. Polymerase reactions were carried out by adding klenow exo-minus DNA polymerase
(Epicentre Biotechnologies, Madison, WI) to a premixed solution containing DNA primer(s) (P1 and
P2, table 3.1) and DNA template(s) (T1 and T2, table 3.1), dNTPs (dATP, dCTP and TTP, Epicentre
Biotechnologies, Madison, WI), dNTP substrate (dGTP/ SedGTP) and DTT in klenow exo-minus DNA
polymerase 10X reaction buffer at 37 °C. For the full length primer extension experiments, the reaction mixtures were incubated at 37 °C for 2 hr. and quenched by the addition of the gel loading dye
solution (5 μL each, containing 50 % glycerol, 0.60 % xylene cyanol, 0.60 % bromophenol blue, 20
mL of 1 mM EDTA, saturated urea). The analysis was performed on 19%, polyacrylamide gel electrophoresis (PAGE). For the time course polymerization reactions, aliquots (5 μL) were removed at
designated time points, and combined with gel loading buffer (5 μL). Reaction progress was monitored over time by 19% denaturing gel electrophoresis. For single nucleotide enzymatic incorporation reactions, no other dNTPs, except for substrate dNTPs (dGTP/ SedGTP), were added to the reac-
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tion mixture. The reaction mixtures were incubated at 37 °C for 1 hr. and analyzed on 19%, polyacrylamide gel. Polymerase reactions contained primer (1.5 μM), template (5 μM), dNTPs (0.1 mM
each), DTT (5 mM), and 10X reaction buffer (1X) in a final reaction volume of 5 μL.
4.4.6 Nuclease Resistance Studies of dG-DNA and SedG-DNA
Enzymatic digestion of dGTP and SedGTP, by Exonuclease III (Promega Corporation, Madison, WI), was studied over time. Primer (P2) was 5'-32P-labeled using T4 polunucleotide kinase and
[γ-32P]-ATP. The DNA polymerization was performed using primer P2 (1.5 μM), template T2 (5
μM), dGTP /SedGTP and other dNTPs (0.1 mM), DTT (5 mM), and Klenow exo(-) DNA polymerase
(0.02 U/μL) at 37 °C for 2 h. The polymerized DNA was extracted by NaCl (0.3 M)/ ethanol (3 volumes) precipitation. The dG-DNA and SedG-DNA were dissolved in Exonuclease III 10X Reaction
Buffer (660mM Tris-HCl (pH 8.0) and 6.6mM MgCl2; final concentration: 1X) and were enzymatically digested using Exonuclease III (0.0002 U/μL) at 37 °C. Aliquots of the reaction mixture were taken at the indicated time points and quenched with gel loading buffer and analyzed by 19% polyacrylamide gel electrophoresis (figure 4.10).
4.5

Results and Discussion
4.5.1 Synthetic Design

6-Se-2'-deoxyguanosine-5'-triphosphate (10, SedGTP, scheme 4.1) was synthesized via a “new
synthetic methodology” developed in our laboratory for protection-free triphosphate synthesis
(229,230).

In

this

strategy,

2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one

and

tri-n-

butylammonium pyrophosphate are used to form a triphosphite intermediate which reacts with the
nucleoside to form P2, P3-dioxo-P1-5'-nucleosidylcyclotriphosphite (8). The synthesis of nucleoside
N2-tBPAc-6-CE-Se-dG (3) is outlined in scheme 2.1. The nucleoside 3 was selectively phosphitylated
by a mild phosphitylating reagent generated in situ from the reaction of 2-chloro-4H-1,3,2benzodioxaphosphorin-4-one and tri-n-butylammonium pyrophosphate. The cyclic phosphite in-
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termediate (8) so obtained was oxidized and hydrolyzed togenerate N2-tBPAc-6-CE-Se-dGTP (9).
The cyanoethyl and (4-tert-butyl-phenoxy)-acetyl protecting groups were removed under ultra
mild conditions (0.05 M K2CO3 in 4:1 methanol/water) to generate 6-Se-2'-deoxyguanosine-5'triphosphate (10). The SedGTP was purified by HPLC, analyzed by UV-Vis and HPLC and characterized using mass spectrometry and NMR (1H, 13C, 31P) spectroscopy.

Scheme 4.1Synthesis of 6-seleno-2'-deoxyguanosine-5'-triphosphate (SedGTP).
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4.5.2 Absorption and Emission Properties
The native 2'-deoxyguanosine-5'-triphosphate (dGTP) shows an absorption maximum at
252 nm. The N2-[2-(4-tert-butyl-phenoxy)acetyl]-6-(2-cyanoethyl)seleno-2'-deoxyguanosine-5'triphosphate (9) shows two discreet absorption bands at 256 nm and 305 nm (figure 3.1). When
the protecting groups are completely removed, the resulting 6-Se-2'-deoxyguanosine-5'triphosphate (10) shows absorption maximum at 357 nm (~ 105 nm red shift compared to the native dGTP). Under basic conditions, 6-Se-2'-deoxyguanosine-5'-triphosphate deprotonates and
forms a dimer. The triphosphate dimer shows an absorption maximum around 330 nm. The dimer
can be reduced by using B2H6-tetrahydrofuran complex or dimer formation can be avoided by keeping the solution pH slightly acidic (< 6.5). HPLC analysis of commercial dGTP and synthesized
SedGTP

(10), at 260 nm and 360 nm, further supported our observation (figure 4.2). SedGTP absorbs

at both 260 nm (slightly) and 360 nm (strongly), whereas native dGTP has no absorbance at 360
nm.

Figure 4.1 Absorption spectra of dGTP (—), N2-tBPAc-6-CE-Se-dGTP (—),SedGTP (—), and SedGTP-dimer (—) in water at
25 ˚C.
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Motivated by the exciting emission behavior of the 6-Se-2'-deoxyguanosine (4), we decided
to investigate the fluorescence properties of 6-Se-2'-deoxyguanosine-5'-triphosphate (10). The triphosphate 10 is fluorescent at physiological pH 7.3. Unlike the nucleoside 4 (which has maximum
emission at 390 nm with an excitation at 305 nm, figure 2.12), the triphosphate 10 has a red shifted
emission at 445 nm and the excitation wavelength of 380 nm is close to its absorption maximum (~
360 nm) (figure 4.3). In general the fluorescence emission from

SedGTP

is low compared to the

emission from SedG, but it is measureable. A pH dependant emission profile for SedGTP was obtained
using solutions with pH 1 – 11 and it was observed that the triphosphate has maximum fluorescence at pH 7.3 (figure 4.3). Concentration-dependent fluorescence profile of SedGTP at pH 7.3 is
presented in figure 4.4. On further analysis, compound 9 was found to be non-emissive under all the
experimental conditions.

Figure 4.2 RP-HPLC analysis of dGTP and SedGTP [monitored at 260 nm (black) and 360 nm (red)]: (a) and (b) commercial dGTP (retention time: 12.4 min); (c) and (d) synthesized SedGTP (retention time: 13.6 min); (e) and (f) co-injection of
commercial dGTP and synthesized SedGTP (retention times: 12.4 and 13.6min, respectively).
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Figure 4.3Fluorescence spectra of SedGTP in aqueous solutions: (A) Excitation spectra of SedGTP as a function of pH at 25
˚C; the emission wavelength was 445 nm. (B) Emission spectra of SedGTP as a function of pH at 25 ˚C, with excitation at
380 nm.

Figure 4.4 Concentration-dependent fluorescence spectra of SedGTP at pH 7.3: (A) Excitation spectra of SedGTP at pH 7.3
and 25 ˚C; the emission wavelength was 450 nm. (B) Emission spectra of SedGTP at pH 7.3 and 25 ˚C; the excitation wavelength was 380 nm.

4.5.3 Enzymatic Synthesis of dG-DNA and SedG-DNA
To investigate the incorporation efficiency of 6-Se-2'-deoxyguanosine-5'-triphosphate (10) into
DNA, polymerization reactions were performed in the presence of klenow exo minus DNA polymerase (Kf-). A list of DNA primers and templates used for the primer extension reactions is presented
in table 4.1.
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Table 4.1 Sequences of DNA primers and templates used for the enzymatic incorporation of SedGTP. The underlined bases
are the sites for dGTP and SedGTP incorporation.
Primers:

P1 (17-mer) 5'-d-TAG CGG GTT GCT GGT GG -3'
P2 (21-mer) 5'-d-GCG TAA TAC GAC TCA CTA TAG-3'

Templates: T1 (21-mer) 3'-d-ATC GCC CAA CGA CCA CCC TGG- 5'
T2 (55-mer) 3'-d-CGC ATT ATG CTG AGT GAT ATC CGT TGG ACT ACT CCG GCT TTCCGG CTT TGC ATG T -5'

Single nucleotide incorporation of the dGTP and SedGTP into DNA was studied using a short
DNA template (T1). The DNA polymerization was performed with primer (1.5 μM), template (5
μM), dGTP /SedGTP (0.1 mM), and Klenow exo(-) DNA polymerase (0.002 U/μL) and analyzed by
19% polyacrylamide gel electrophoresis. Like dGTP, SedGTP also acts as a good substrate for DNA
polymerase (figure 4.5). From the intensity of the product DNA band it appears that the SedGTP is
well recognized by the DNA polymerase and the single selenium-atom substitution does not have a
significant structural impact. The single nucleotide incorporation was confirmed by MALDI-MS
analysis (figure 4.6). A 64 Dalton mass difference between the resultant dG-DNA and SedG-DNA indicates the incorporation of Se-modified guanosine base.

Figure 4.5 Enzymatic incorporation of a single nucleotide (dGTP and SedGTP) into DNA (T1): a) Enzymatic incorporation
of dGTP and SedGTP by Klenow exo(-) on DNA template T1. b) Gel electrophoresis autoradiography of the polymerization
reaction. Lanes 2 and 3 show single nucleotide incorporation forming 18-nucleotide long DNA.
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Figure 4.6 MALDI-MS analysis for enzymatic incorporation of a single nucleotide (dGTP and SedGTP) into DNA (T1): MS
spectra of dG-extended DNA (O-18-mer, calculated m/z for [M+H]+: 5644, observed m/z for [M+H]+:5648); MS spectra of
SedG-extended DNA (Se-18-mer, calculated m/z for [M+H]+: 5708, observed m/z for [M+H]+: 5712); T1: calculated m/z for
[M+H]+:6322, observed m/z for [M+H]+:6329.

We also performed a time-course experiment, using P1/T1 for single nucleotide incorporation, to compare the efficiency of incorporation (and recognition) of SedGTP with native dGTP. The
single nucleotide incorporation was performed with primer (1.5 μM), template (5 μM), dGTP
/SedGTP (0.1 mM), and Klenow exo(-) DNA polymerase (0.0002 U/μL) at 37 °C and analyzed by
19% polyacrylamide gel electrophoresis. The experiment was monitored over a period of 120 min.
Aliquots of the reaction mixture were taken at the indicated time points and quenched with gel
loading buffer. The results are presented as gel electrophoresis autoradiography in figure 4.7 (a). It
was observed that SedGTP is more selective in controlling the reaction at single nucleotide incorporation, whereas native dGTP shows extended n+2 DNA product (probably as a result of formation of
G/T wobble pair) along with the desired n+1 DNA. Thus, under these conditions, the polymerization efficiency of dGTP and SedGTP appear similar (figure 4.7 (b));the single atom selenium modification inhibits G/T wobble pair formation.
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Figure 4.7 Time course of the incorporation of single nucleotide (dGTP and SedGTP) into DNA (T1): a) Gel electrophoresis
autoradiography of the incorporation reaction over time (120 min). b) Plot of the incorporation of dGTP and SedGTP into
DNA with respect to time.
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Figure 4.8 Enzymatic incorporation of all natural dNTPs, dGTP and SedGTP into DNA (T2): a) Enzymatic incorporation of
all dNTPS, dGTP and SedGTP by Klenow exo(-) on DNA template T2. b) Gel electrophoresis autoradiography of the
polymerization reaction.

We also studied the efficiency of incorporation of more Se-modified guanosine nucleotides
using a longer DNA template (T2). The incorporation was carried out by extending a 21 nucleotide
primer along a 55 nucleotide template. The DNA polymerization was performed with primer (1.5
μM), template (5 μM), dGTP /SedGTP and other dNTPs (0.1 mM), and Klenow exo(-) DNA polymerase (0.04 U/μL) and analyzed by 19% polyacrylamide gel electrophoresis. Figure 4.8 shows the
primer extension using T2 template. This polymerization involved the incorporation of ten SedGTP,
and in two locations along the template, two SedGTP had to be incorporated consecutively. The full
extension SedG-DNA product migrated faster compared with the product band for dG-DNA, probably due to the electronic effect of selenium atom. This difference in DNA mobility is more pronounced for the 55 nucleotide long product, which involves the incorporation of ten SedGTP, than
for the 18 nucleotide product obtained by extending a 17 nucleotide primer along a 21 nucleotide
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template, involving the incorporation of only one SedGTP (figure 4.5 (b)). Further experiments are
needed to confirm/demonstrate the efficient incorporation of multiple SedGTPs.

Figure 4.9 Time course of the incorporation of all natural dNTPs, dGTP and SedGTP into DNA (T2): a) Gel electrophoresis
autoradiography of the polymerization reaction over time (120 min). b) Plot of the incorporation of dGTP and SedGTP
(along with other dNTPs) into DNA with respect to time.

Through these enzymatic incorporation studies we observed that SedGTP was tolerated as a
substrate for DNA polymerase. We performed a time-course experiment for this primer-template
set as well to compare the efficiency of incorporation of multiple modified bases. The DNA polymerization was performed with primer (1.5 μM), template (5 μM), dGTP /SedGTP and other dNTPs (0.1
mM), and Klenow exo(-) DNA polymerase (0.0015 U/μL for dGTP and 0.015 U/μL for SedGTP ) at 37
°C and analyzed by 19% polyacrylamide gel electrophoresis. Aliquots of the reaction mixture were
taken at the indicated time points and quenched with gel loading buffer. The results are presented
as gel electrophoresis autoradiography in figure 4.9 (a). Under the experimental conditions used,
the incorporation of dGTP was more efficient yielding the 55 nucleotide dG-DNA in ~ 5 min. On the
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other hand, the polymerization involving SedGTP was stalled for ~ 5 min. at some mid-point but
gave full length 55–mer SedG-DNA product after 90 min. of incubation. Figure 4.9 (b) shows a plot
of the incorporation of dGTP and SedGTP (along with other dNTPs) into the DNA T2 with respect to
time. This study indicated that single atom modification in SedGTP is somewhat less tolerated as a
substrate by the DNA polymerase compared with the native dGTP while extending longer DNAs.
4.5.4 Nuclease Resistance Studies of dG-DNA and SedG-DNA

Figure 4.10 Time course of the enzymatic digestion of dGTP and SedGTP incorporated DNA with Exonuclease III. a) Gel
electrophoresis autoradiography; b) plot of digestion of dG-DNA and SedG-resistive DNA with respect to time.

We also conducted some experiments to study the resistance of the SedG-DNA, in comparison to the native dG-DNA, towards nucleases. For this, we synthesized the DNA along the 55 nucleotide template (T2) and purified it by NaCl/ethanol precipitation (to remove any unconsumed
dNTPs and short fragments). The precipitated 55 nucleotide long DNAs, dG-DNA with ten dGTP and
SedG-DNA

with ten SedGTP, were treated with exonuclease III and the reaction was monitored over a

period of 25 min. Aliquots of the reaction mixture were taken at the indicated time points and
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quenched with gel loading buffer. The gel electrophoresis autoradiography and plot of digestion of
dG-DNA and SedG-DNA with respect to time are shown in figure 4.10. It was observed that dG-DNA
started fragmenting within 5 minutes of treatment with nuclease, whereas the

SedG-DNA

offered

more resistance to the nuclease, losing only few nucleotides over the course of the experiment.

4.6 Conclusions
Herein, we report the first chemical synthesis of 6-Se-2'-deoxyguanosine-5'-triphosphate
(SedGTP). We have demonstrated that the simple, one-pot and protection-free method for triphosphate synthesis developed in Dr. Huang’s laboratory could be successfully used for the synthesis of
modified triphosphates. The synthesized SedGTP has distinct optical properties. With only a single
atom modification, this Se-modified triphosphate is bright yellow (like the nucleoside

SedG)

and

measurably fluorescent at physiological pH 7.3. It displays a discreet absorption band at ~ 360 nm.
In general the fluorescence emission from SedGTP is low compared to the emission from SedG, but it
is measureable. With an excitation wavelength of 380 nm,

SedGTP

displays a weak fluorescence

emission at 445 nm. The synthetic Se-DNA is significantly nuclease-resistant compared to the native DNA, and is efficiently recognized by DNA polymerase. Since the SedGTP is yellow in color and
measurably fluorescent at physiological pH, it can used as an effective biochemical probe for exploring the dynamics of interactions of nucleotides with proteins and small molecules. The SedG-DNA
being yellow in color, also offers potential applications as deoxyribonucleic acid (DNA) visualization
probe.
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5

SYNTHESIS OF 6-SELENOGUANOSINE-5'-TRIPHOSPHATE

5.1 Selenium Functionalized Ribonucleside Triphosphates
Selenium, in the form of selenocysteine (Sec), has been found in several charged tRNAs such
as tRNA (Sec). This Se-containing tRNA is the longest characterized mammalian tRNA (90 nt in
length) and its anticodon is complementary to the stop codon UGA (231,232). The secondary structures of tRNA (Sec) differ among the three domains of life: bacteria, eukarya and archaea (233,234).
The selenium nucleoside, identified as 5-[(methylamino)methyl]-2-selenouridine (mnm5se2U), is
often found at the first or wobble position of the anticodon loop of tRNA (43,44). While the precise
function of selenium at the C-2 position and the comprehensive utility of Se-derivatized tRNAs are
not delineated, this modification is essential for catalysis and regulation and probably capable of
augmenting translational efficiency and efficacy (45). The substitution of oxygen with selenium in
the nucleobases permits a search for novel aspects of nucleic acid base-pairing and stacking interactions at the atomic level. Huang and coworkers have developed diverse building units like, 6seleno-guanosine (Se6G) (50) and 2-seleno-uridine (Se2U) (53), for their incorporation into RNA by
solid-phase synthesis. The 2-seleno-modification has a pronounced ability to discriminate wobble
base-pairing. Structural and biophysical studies on 2-seleno-uridine containing oligonucleotides
highlight the increased fidelity of Se2U/A base pairs. Huang’s research group was the first to develop the enzymatic synthesis of stereo-defined phosphoroselenoates (PSe) (217,218). This enzymatic
synthesis is based on the recognition of the SP and/or RP diastereomers of α-Se-dNTPs or α-Se-NTPs
by the polymerases. Only the SP diastereoisomer of α-Se-ATP is efficiently recognized by T7 RNA
polymerase, enabling synthesis of diastereomerically-pure PSe-RNAs (218). Later, the α-Se-NTPs
(α-Se-ATP, α-Se-GTP, α-Se-CTP andα-Se-UTP) were used to transcribe hammerhead ribozyme to
generate diastereomerically-pure PSe-RNAs for structural and mechanistic studies (235). Recently,
Huang and coworkers have developed a novel, efficient, one-pot synthesis of α-Se-NTPs without
protecting the nucleosides and used this method for the large-scale synthesis of α-Se-NTPs for PSe-
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RNA transcription (48). Moreover, Se-modification renders the PSe-RNAs resistant to nucleases,
thereby making them potential therapeutic agents. Recently, we have demonstrated that the synthesized SeUTP is stable and recognizable by T7 RNA polymerase (51). Under the optimized conditions, the transcription yield of SeU-RNA can reach up to 85% of the corresponding native RNA. Furthermore, the transcribed SeU-hammerhead ribozyme has the similar activity as the corresponding
native, which suggests usefulness of SeU-RNAs in function and structure studies of non-coding RNAs.
Herein, we report the synthesis of 6-selenoguanosine-5'-triphosphate (SeGTP). With only a
single atom modification, this Se-modified triphosphate is bright yellow in color. It could potentially
be used for exploring the structure and dynamics of RNA and its complexes with proteins and small
molecules/ligands.
5.2 Materials and Methods
5.2.1 Synthesis of N2-Phenoxyacetyl-6-(2-Cyanoethylseleno)-Guanosine
N2-phenoxyacetyl-6-(2-cyanoethylseleno)-guanosine (4, scheme 5.1) was synthesized from
from commercially available starting material N2-phenoxyacetyl-2'-O-(tert-butyldimethylsilyl)-5'O-(4,4'-dimethoxytrityl)guanosine, 1 . 2'-O-(tert-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl)-2phenoxyacetyl-6-(2-cyanoethyl)-selenoguanosine nucleoside (2) was synthesized from compound
1 using a published procedure (50). N2-phenoxyacetyl-6-(2-cyanoethylseleno)-guanosine (4) was
obtained from compound 2 by selectively removing the 2'-O-(tert-butyldimethylsilyl) and 5'-O(4,4'-dimethoxytrityl) protecting groups (scheme 5.1). For deprotecting the 2'-TBDMS group
TEA.3HF was used. Compound 2 was weighed in a 25 mL r.b. flask (2 g, 2.11 mmol) and dissolved in
THF (5 mL). The desilylation reagent TEA.3HF (1 mL) was then added to the reaction mixture. The
reaction was allowed to stir overnight at 40 °C. During, this time the reaction (desilylation) was
about 90 % complete (as monitored on TLC in 10 % methanol in dichloromethane). The reaction
mixture was neutralized and the solvent was evaporated under reduced pressure. No further puri-
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fication was performed and the crude product was used as such for detritylation reaction. For
deprotecting the 5'-DMTr group, dichloroacetic acid (3 %, 1 mL) was added to this crude reaction
mixture and stirred at room temperature. The trityl cation was quenched with methanol (1 mL).
More dichloroacetic acid was added. Reaction progress was monitored by TLC (10 % methanol in
dichloromethane). The reaction mixture was neutralized and the solvent was evaporated under reduced pressure to yield the crude product 4. The mixture was diluted with ethyl acetate and
washed with saturated NaCl (3 x 10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and concentrated to yield crude product. The crude product was purified via silica gel column
chromatography (solvent gradient from pure dichloromethane up to 7 % methanol in dichloromethane) to give N2-phenoxyacetyl-6-(2-cyanoethylseleno)-guanosine (4)as a dirty white solid
(0.8886 g, 79 %). HRMS (ESI-TOF): molecular formula, C21H22N6O6Se; [M+H]+: 535.0848 (calc.
535.0839);1H NMR (400 MHz, CD3SOCD3) δ: 3.17-3.21 (m, 3H) and 3.54-3.57 (m, 3H)[Se-CH2-CH2CN, Se-CH2-CH2-CN and H-5'), 3.94 (m, 1H, H-4'), 4.17 (br, 1H, H-3'), 4.57 (br, 1H, H-2'), 4.99 [(2H,
CH2-O), (1H, 5'-OH)], 5.23 and 5.53 (b, 2 H, 2'-OH and 3'-OH), 5.93-5.95 (d, J1'-2'= 8 Hz, 1H, H-1'),
6.94-6.97 (m, 3H, CH-arom), 7.31 (t, J = 8 Hz, 2H, CH-arom), 8.64 (s, 1H, H-8), 10.88 (s, 1H, NH); 13C
NMR (100 MHz, CD3SOCD3) δ: 18.48 and 19.03 (Se-CH2-CH2-CN), 61.17 (C-5'), 67.12 (CH2-O), 70.24
(C-3'), 73.81 (C-2'), 85.65 (C-4'), 87.25 (C-1'), 114.49 120.94 and 129.50 (CH-arom), 119.97 (CN),
130.32 (C-5), 142.72 (C-8), 148.93 (C-6), 151.77 (C-4), 157.51 (C-2), 157.87 (C-arom), 167.28
167.23 (C=O).
5.2.2 Synthesis of 6-Selenoguanosine-5'-Triphosphate
N2-phenoxyacetyl-6-(2-cyanoethylseleno)-guanosine (4, 25 mg, 0.047 mmol) was weighed
in a 10 mL r.b. flask and dried overnight under vacuum. 2-chloro-4H-1,3,2-benzodioxaphosphorin4-one (19 mg, 2 eq.) was dried in a flask for 10 min. Tri-n-butylammonium pyrophosphate (108 mg,
5 eq.) was dried overnight in a separate flask, under high vacuum. The pyrophosphate was dissolved in DMF (0.3 mL) with additional TBA (0.1 mL) and transferred into the flask containing 2-
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chloro-4H-1,3,2-benzodioxa-phosphorin-4-one, dissolved in dioxane (0.4 mL). The mixture was
flushed with argon and allowed to stir at room temperature. After 45 min. the mixture was transferred into the flask containing vacuum dried compound 4 dissolved indioxane (0.4 mL) and DMF
(0.15 mL). The combined contents were allowed to stir at room temperature for 4 h to yield the cyclic phosphite intermediate 5 (scheme 5.2). The cyclic-phosphite 5 was then oxidized by adding iodine solution (0.02% I2/THF/Pyridine/H2O, 1 mL). The mixture was stirred for 1 h and then hydrolyzed with water (3 mL) and allowed to stir at room temperature for 4 h to ensure complete hydrolysis. The sample was precipitated using NaCl (0.3 M)/ ethanol (3 volumes). The precipitate was
analyzed by recording a TLC (5:3:2 of iso-PrOH:NH3.H2O:H2O). The crude N2-phenoxyacetyl-6-(2cyanoethyl)selenoguanosine-5'-triphosphate, N2-n-PAc-6-CE-SeGTP, 6 was then purified by reverse
phase HPLC. HRMS (ESI-TOF): molecular formula, C21H25N6O15P3Se; [M-H+]-: 772.9684 (calc.
772.9683); 1H NMR (400 MHz, D2O) δ: 3.54 (t, J = 6.72 and 6.76 Hz, 2H, Se-CH2-CH2-CN), 4.28 (b, 2H,
H-5'), 4.42 (b, 1H, H-4'), 4.62 (b, 1H, H-3'), 4.89 (br, 3H, CH2-O and H-2'), 6.16-6.18 (d, J1'-2'= 5.56
Hz, 1H, H-1'), 6.97-7.02 (m, 3H, CH-arom),7.29-7.33 (t, J = 7.64 and 7.72 Hz, 2H, CH-arom), 8.60 (s,
1H, H-8); 13C NMR (100 MHz, D2O) δ: 19.54 and 19.88 (Se-CH2-CH2-CN), 66.14 (C-5'), 67.98 (CH2-O),
71.24 (C-3'), 75.25 (C-2'), 84.97 (C-4'), 88.08 (C-1'), 115.21, 122.88 and 130.59 (CH-arom), 121.53
(CN), 131.03 (C-5), 143.35 (C-8), 149.13 (C-6), 151.94 (C-4), 157.50 (C-2), 180.68 (C=O);31P NMR
(162 MHz, D2O) δ: -23.13 (t, Jβ = 17.82 and 19.44 Hz, 1P, P-β), -11.48 (d, Jα = 19.44 Hz, 1P, P-α), 10.46 (d, Jγ = 19.70 Hz, 1P, P-γ).
HPLC purified N2-n-PAc-6-CE-SeGTP (6)was stored, as a dry pale green solid, in -80 ⁰C refrigerator until further use. Only a small portion of the purified sample was treated with 0.05 M
K2CO3 (4:1 = MeOH: H2O; 5 mL) at room temperature for 12 h, to remove the 2-cyanoethyl and
phenoxyacetyl protecting groups. The pure 6-selenoguanosine-5'-triphosphate (SeGTP, 7, scheme
5.2)was recovered as a bright yellow solid by NaCl (0.3 M)/ ethanol (3 volumes) precipitation. The
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molecular formation of SeGTP was confirmed by MS analysis. HR-MS (ESI-TOF): molecular formula,
C10H16N5O13P3Se; [M-H+]-: 585.9030 (calc. 585.9050).
5.2.3 HPLC Purification of 2-Phenoxyacetyl-6-(2-Cyanoethylseleno)-Guanosine-5'Triphosphate
The crude N2-n-PAc-6-CE-SeGTP (6)was purified and analyzed by RP-HPLC. The N2-n-PAc6-CE-SeGTP was eluted at 305 nm, with a flow-rate of 6 mL/min [buffer A: 20 mM TEAAc (pH 7.1)
in water; buffer B: 20 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 5 % buffer
B to 100 % buffer B in 30 min. The desired peak was collected and the buffer was removed by
lyophilization. The pure fractions were analyzed on Welchrom C18-XB column (4.6*250 mm) and
measured at a flow rate of 1.0 mL/min and a linear gradient of 0 to 40 % buffer B in 25 min [buffer
A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH 7.1)in 50% acetonitrile]. The HPLC
profile of the purified N2-n-PAc-6-CE-SeGTP, at 260 nm and 305 nm wavelengths, is shown in figure
5.1.
5.3 Results and Discussion
5.3.1 Synthetic Design
2'-O-(tert-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl)-2-phenoxyacetyl-6-(2-cyanoethyl)-selenoguanosine (2, scheme 5.1) was synthesized from compound 1 using a published procedure (50). N2-phenoxyacetyl-6-(2-cyanoethyl)selenoguanosine nucleoside (N2-n-PAc-6-CE-SeG,
4) was obtained from compound 2by selective deprotection of the 2'-TBDMS and 5'-DMTr groups.
Since strong basic conditions can cause deselenization of the base, phenoxyacetyl (n-Pac) was used
to protect the 2-NH2 of this guanosine nucleoside and 2-cyanoethyl was used to protect selenium
(to avoid any oxidation under the experimental conditions). Both these groups can be deprotected
under ultramild conditions (0.05 M K2CO3 in methanol).
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Scheme 5.1 Synthesis of 2-phenoxyacetyl-6-(2-cyanoethylseleno)-guanosine, 4.

N2-n-PAc-6-CE-SeG

was

then

used

to

synthesize

N2-phenoxyacetyl-6-(2-

cyanoethyl)selenoguanosine-5'-triphosphate (N2-n-PAc-6-CE-SeGTP, 6) via the “new synthetic
methodology” developed in our laboratory for protection-free triphosphate synthesis (229,230). In
this strategy, the triphosphate intermediate, formed by the reaction of 2-chloro-4H-1,3,2benzodioxaphosphorin-4-one with tri-n-butylammonium pyrophosphate, reacts with the nucleoside to form P2, P3-dioxo-P1-5'-nucleosidylcyclotriphosphite (5). The synthesis of nucleoside N2-nPAc-6-CE-SeGTP (6) is outlined in scheme 5.2. The N2-n-PAc-6-CE-SeGTP was purified and analysed
by HPLC, and characterized using mass spectrometry and NMR (1H, 13C, 31P) spectroscopy.
This protected triphosphate will be further deprotected under ultra mild conditions (0.05 M
K2CO3 in 4:1 methanol/water) to generate 6-selenoguanosine-5'-triphosphate (SeGTP, 7). The synthesized and purified SeGTP will be used as a substrate for RNA transcription using T7 RNA polymerase.
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Scheme 5.2 Synthesis of 6-selenoguanosine-5'-triphosphate (SeGTP).
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5.3.2 HPLC Purification of 2-Phenoxyacetyl-6-(2-Cyanoethylseleno)-Guanosine-5'Triphosphate
The crude N2-n-PAc-6-CE-SeGTP (6)was purified and analyzed by RP-HPLC. The N2-n-PAc6-CE-SeGTP was eluted at 305 nm, with a flow-rate of 6 mL/min [buffer A: 20 mM TEAAc (pH 7.1)
in water; buffer B: 20 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 5 % buffer
B to 100 % buffer B in 30 min. The desired peak was collected and the buffer was removed by
lyophilization. All the dry fractions were analyzed on Welchrom C18-XB column (4.6*250 mm) and
measured at a flow rate of 1.0 mL/min and a linear gradient of 0 to 40 % buffer B in 25 min [buffer
A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH 7.1) in 50% acetonitrile (figure
5.1).

Figure 5.1 RP-HPLC analysis of n-PAc-6CE-SeGTP, 6, monitored at 260 nm (black) and 305 nm (red)] (retention time:
31.04 min).

5.3.3 Proposed Study
The synthesized and purified 6-selenoguanosine-5'-triphosphate (SeGTP, 7) will be enzymatically incorporated into RNA. It may or may not act as a good substrate for transcribing RNA
using T7 RNA polymerase. Since G is the first base introduced in any transcription process, there
might be a need for certain optimization of the experimental conditions to facilitate transcription.
This study might help us better understand the fidelity of the T7 RNA polymerase. Some un-natural
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RNA polymerases might also be used for transcribing SeGTP into RNA. These experiments might also help in generating longer selenium derivatized RNAs for exploring the structure and dynamics of
RNA and its complexes with proteins and small molecules/ligands.

5.4 Conclusions and Future Prospects
Herein, we report the first chemical synthesis of 6-selenoguanosine-5'-triphosphate (SeGTP).
We have demonstrated that the simple, one-pot and protection-free method for triphosphate synthesis developed in Dr. Huang’s laboratory could be successfully used for the synthesis of modified
triphosphates. With only a single atom modification, this Se-modified triphosphate is bright yellow
in color. It could potentially act as a good substrate for generating longer selenium derivatized
RNAs for exploring the structure and dynamics of RNA and its complexes with proteins and small
molecules/ligands. Since the single-atom selenium modification renders a strong yellow color to
the synthetic SeG-RNA (50), it could be potentially used as an RNA visualization probe.
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SYNTHESIS ANDBIOCHEMICAL STUDY OF S-MERCAPTOPROPYL-5-

(MERCAPTO-METHYL)-2'-DEOXYURIDINE-5'-TRIPHOSPHATE
6.1 Introduction
The use of nanoparticles is evolving in present day therapeutics. They promise a bright future in photodiagnostics and photothermal therapy of cancers and other diseases(236,237). In particular, there has been more focus on the gold nanoparticles (AuNPs) in biochemistry and
nanomedicine. A variety of ligands have been discovered to stabilize AuNPs, but the best proven
stabilizers have been thiolates. Thiolates form robust AuNPS by the virtue of strong Au-S bond between soft acid Au and the soft thiolate base. Functional thiolates have also been used along this
line. Oligonucleotides, peptides and PEGs are easily attached to AuNPs in this way(236). AuNPs
have been successfully used as colorimetric biosensors which utilize the color change arising from
the interparticle plasmon coupling during AuNP aggregation (red-to-purple or blue) or
redispersion of an AuNP aggregate (purple-to-red) (238-244). This nature of gold nanoparticles has
been applied for sensing enzymatic activity as well (245,246). Exploring enzymatic reactions involving nucleoside triphosphates as substrates is of vital significance in molecular biology.
The stability of non-modified AuNPs is sensitive to various factors. Hence, different methods
have been designed to increase their stability, which can be accomplished by using different kinds
of stabilizers like, surfactant, polymer, nucleoside or oligonucleotide. Nucleobases are capable of
binding with the citrate-capped AuNPs by displacing the weakly bound citrate ions via metal-ligand
interactions. It has also been demonstrated that the nucleotides (adenosine mono-, di- and triphosphates) are furthercapable of stabilizing the AuNPs in the order ATP> ADP> AMP (245).
Cytidine triphosphate (CTP) stabilized AuNPs have been useful probes for detection of calcium ions
(Ca2+) with high sensitivity and selectivity (247,248).
Herein, we report the synthesis of a novel thiol functionalized triphosphate, Smercaptopropyl-5-(mercapto-methyl)-2'-deoxyuridine-5'-triphosphate (10, scheme6.2). The modi-
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fication has been introduced to increase the ability of TTP to stabilize AuNPs. The synthetic DNA
obtained by the incorporation of this thiol-functionalized TTP will be further used to study the stabilization of gold nanoparticles with reference to the native DNA. The study will be based on the
strong affinity of gold nanoparticles for thiol-functionality. The modified DNA will also find use and
application in DNA/RNA microchip surface functionalization for rapid detection of various diseases
and pathogens.

6.2 Materials and Methods
6.2.1 Synthesis of S-(3-(Acetylthio)propyl)-5-(Mercaptomethyl)-2'-Deoxyuridine
S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine was synthesized from thymidine in seven steps (scheme 6.1). 3', 5'-bis-O-(tert-butyldimethylsilyl)-thymidine(1): Thymidine (2
g, 0.0083 mol), tert-butyldimethylsilyl chloride (TBDMSi-Cl) (2.74 g, 0.0182 mol) and imidazole
(3.39 g, 0.0498 mol) ) were weighed out in a 100 mL flask and dissolved in anhydrous DMF (10
mL).The reaction mixture was stirred for 12 h. at room temperature. The reaction progress was
monitored by recording TLC (20 % ethyl acetate in CH2Cl2). After the complete consumption of the
starting material, the reaction mixture was poured into ethyl acetate (20 mL) and extracted with
sodium chloride (NaCl) solution (sat., 3 x 20 mL). The organic phase was dried over MgSO4. The solvent was evaporated under reduced pressure. The pale green oily syrup was purified via silica gel
flash column chromatography (1 % MeOH in CH2Cl2) to give 3', 5'-bis-O-(tert-butyldimethylsilyl)thymidine(1, 3.83 g, 98 %) as a white flaky solid. HRMS (ESI-TOF): molecular formula,
C22H42N2O5Si2; [M+H+]+: 471.2710 (calc. 471.2705); [M-H++Na+]+: 493.2557 (calc. 493.2524); 1H
NMR (400 MHz, CDCl3) δ: 0.08-0.11 (m, 12H, 4 x CH3-Si), 0.88-0.93 (m, 18H, 6 x CH3-tBu), 1.92-2.01
(m, 3H, H-2' and CH3-), 2.25 (b, 1H, H-2'), 3.78-3.93 (b, m, 3H, H-3' and H-5'), 4.40 (br, 1H, H-4'),
6.35 (b, 1H, H-1'), 7.47 (b, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ: -5.35 to -4.39 (CH3-Si), 12.73 (C5-
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CH3), 18.18 and 18.56 [tBuC-(CH3)3], 25.61-26.17 (CH3-tBu), 41.56 (C-2'), 63.11 (C-5'), 72.38 (C-3'),
84.94 (C-4'), 87.98 (C-1'), 111.01 (C-5), 135.57 (C-6), 150.66 (C2=O), 164.28 (C4=O).
3', 5'-Bis-O-(tert-butyldimethylsilyl)-5-bromomethyl-2'-deoxyuridine (2): Compound, 1
(400 mg, 0.8497 mmol), N-bromo-succinimide (378 mg, 2.124 mmol), and benzoyl peroxide (6 mg,
0.0248 mmol) were weighed out in a 50 mL flask and dissolved in dry CCl 4 (25 mL). The reaction
was heated to reflux for 1.5 h, during which time the solution changed from colorless to orange. The
appearance of orange color is indicative of formation of bromine in the reaction. The reaction progress was monitored by recording TLC (15 % ethyl acetate in CH2Cl2). The reaction was allowed to
cool and filtered to remove insoluble succinimide. The solvent was evaporated under reduced pressure to yield crude 3', 5'-bis-O-(tert-butyldimethylsilyl)-5-bromomethyl-2'-deoxyuridine (2) as a
yellow solid. The crude compound 2 was used as such, without any further purification, for the next
step (249). HRMS (ESI-TOF): molecular formula, C22H41BrN2O5Si2; [M+H+]+: 549.1806

(calc.

549.1810).
S-acetyl-3',5'-bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'-deoxyuridine(3):

Po-

tassium thioacetate (AcOSK, 388 mg, 3.3972 mmol) was weighed out in the flask containing crude
compound 2 and dried under vacuum for about 15 min. Anhydrous DMF (2 mL) was added to the
reaction flask, under argon atmosphere. The reaction was heated at 70 °C for 2 h. The reaction progress was monitored by recording TLC (15 % ethyl acetate in CH2Cl2). The reaction mixture was
diluted with ethyl acetate (10 mL) and washed with NaCl solution (sat., 5 x 20 mL). The organic layer was dried using anhydrous MgSO4. The solvent was evaporated under reduced pressure to yield
dark brown oily syrup of crude compound 3. The crude product 3 was purified using preparative
TLC plate (12 % EtOAc in CH2Cl2) to yield a brown product. HRMS (ESI-TOF): molecular formula,
C22H44N2O6SSi2; [M-H+]-: 543.2379(calc. 543.2386); 1H NMR (400 MHz, CDCl3) δ: 0.05-0.08 (2 x s,
12H, 4 x CH3-Si), 0.86-0.89 (2 x s, 18H, 6 x CH3-tBu), 2.00 (b, 1H, H-2'), 2.26 (b, 4H, H-2' and CH3CO), 3.72 (s, 1H, C5-CH2-S-), 3.79 (s, 2H, H-5'), 3.90 (s, 1H, H-3'), 4.41 (s, 1H, H-4'), 6.25 (t, 1H, H-1'),
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7.71 (s, 1H, H-6), 9.94 (s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ: -5.34 to -4.58 (CH3-Si), 18.09-18.53
[tBuC-(CH3)3], 25.87-26.08 (CH3-tBu), 30.58 (C5-CH2-), 41.07 (C-2'), 63.14 (C-5'), 72.22 (C-3'), 85.32
(C-4'), 87.93 (C-1'), 110.92 (C-5), 138.52 (C-6), 150.33 (C2=O), 163.13 (C4=O), 195.73 (CH3-CO-).
3',5'-Bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'-deoxyuridine (4): Compound 3
was dissolved in MeOH (3 mL) and hydrolyzed using 1 M NaOH/MeOH solution (1 mL). The reaction progress was monitored by recording TLC (20 % ethyl acetate in CH2Cl2). The reaction completed in 2 h at room temperature. The reaction mixture was neutralized with acetic acid (AcOH)
and the solvent was evaporated under reduced pressure to yield dark brown solid. The crude compound 4 was used as such for the next step.
S-(3-bromopropyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'-deoxyuridine (5): Potassium carbonate (K2CO3, 470 mg, 3.4006 mmol) and dithiothreitol (DTT, 262 mg,
1.6985 mmol) were weighed out in the flask containing crude compound 4, and dried under vacuum for about 15 min. Anhydrous DMF (2 mL) was added to the reaction flask, under argon atmosphere. The reaction was stirred at room temperature for 1 h. Reaction progress was monitored by
TLC (15 % EtOAc in CH2Cl2). 1,3-Dibromopropane (0.8 mL, 0.0078 mmol) was then added drop
wise, with vigorous stirring, to the reaction mixture, under argon atmosphere. The reaction was
stirred at room temperature for 12 h. Reaction progress was monitored by TLC (15 % EtOAc in
CH2Cl2). After the complete consumption of the intermediate formed by the reaction of DTT with
compound 4, the reaction mixture was diluted with ethyl acetate (10 mL) and washed with NaCl
solution (sat., 5 X 20 mL). The organic layer was dried using anhydrous MgSO 4. The solvent was
evaporated under reduced pressure to yield brown oily compound 5. The crude product 5 was purified using preparative TLC plate (12 % EtOAc in CH2Cl2) to yield a golden-brown oily product.
HRMS (ESI-TOF): molecular formula, C25H47BrN2O5SSi2; [M+H+]+: 623.2030(calc. 623.2000); 1H
NMR (400 MHz, CDCl3) δ: 0.04-0.06 (2 x s, 12H, 4 x CH3-Si), 0.86-0.89 (2 x s, 18H, 6 x CH3-tBu), 1.97
(m, 1H, H-2'), 2.29 (m, 1H, H-2'), 2.19 (m, 2H, Br-CH2-CH2-CH2-S-), 3.42-3.51 (m, 6H, C5-CH2-S- and
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Br-CH2-CH2-CH2-S-), 3.74-3.83 (b, 2H, H-3' and H-5'), 3.93 (m, 1H, H-5'), 4.40 (m, 1H, H-4'), 6.30 (t,
1H, H-1'), 7.61 (s, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ: -5.09 to -4.46 (CH3-Si), 18.15-18.58 [tBuC(CH3)3], 25.94 and 26.17 (CH3-tBu), 30.68 (C5-CH2-), 32.14 and 32.46 (Br-CH2-CH2-CH2-S-), 36.24
(Br-CH2-CH2-CH2-S-), 41.51 (C-2'), 63.25 (C-5'), 72.48 (C-3'), 85.37 (C-4'), 88.09 (C-1'), 112.26 (C-5),
137.45 (C-6), 150.25 (C2=O), 163.20 (C4=O).
S-(3(acetylthio)propyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'-deoxyuridine (6): Potassium thioacetate (388 mg, 3.3972 mmol) and compound 5 were weighed out in a
25 mL flask and dried under vacuum for about 15 min. Anhydrous DMF (2 mL) was added to the
reaction flask, under argon atmosphere. The reaction was heated at 70 °C for 3 h. Reaction progress
was monitored by TLC (20 % EtOAc in CH2Cl2). The reaction mixture was diluted with ethyl acetate
(10 mL) and washed with NaCl solution (sat., 5 X 20 mL).The organic phase was dried using MgSO 4.
The solvent was evaporated in vacuo to yield brown oily compound 6. The crude product 6 was purified using preparative TLC plate (12 % EtOAc in CH2Cl2) to yield a golden brown oily product.
HRMS (ESI-TOF): molecular formula, C27H50N2O6S2Si2; [M+H+]+: 619.2733(calc. 619.2727); 1H NMR
(400 MHz, CDCl3) δ: 0.08-0.12 (2 x s, 12H, 4 x CH3-Si), 0.90-0.93 (2 x s, 18H, 6 x CH3-tBu), 1.85-1.89
(m, 1H, H-2'), 1.97-2.04 (m, 1H, H-2'),2.32-2.35, 2.58-2.63 and 2.93-2.99 (m, 9H, CO-CH2-CH2-CH2-Sand CH3-CO-), 3.41-3.47 (m, 2H, C5-CH2-S-) 3.74-3.83 (m, 2H, H-3' and H-5'), 3.93-3.95 (m, 1H, H5'), 4.41 (b, 1H, H-4'), 6.31 (t, 1H, H-1'), 7.61 (s, 1H, H-6);13C NMR (100 MHz, CDCl3) δ: -4.99 to -4.33
(CH3-Si), 18.30-18.74 [tBuC-(CH3)3], 26.07-26.29 (CH3-tBu), 27.90, 29.44, 30.95 and 31.60 (CH3-COCH2-CH2-CH2-S-CH2-C5), 41.59 (C-2'), 63.41 (C-5'), 72.67 (C-3'), 85.50 (C-4'), 88.23 (C-1'), 112.45 (C5), 137.50 (C-6), 150.22 (C2=O), 163.20 (C4=O), 195.76 (CH3-CO-).
S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine (7): Compound 6 (26.7 mg,
0.0431 mmol) was dissolved in THF (1 mL). Triethylamine trihydrofluoride (30 μL, 0.688 mmol)
was added to the reaction flask, under argon atmosphere. The reaction was heated at 45 °C for 5 h.
Reaction progress was monitored by TLC (10 % MeOH in CH2Cl2). The solvent was evaporated un-
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der reduced pressure and the crude product 7 was purified using preparative TLC plate (10 %
MeOH in CH2Cl2) to yield 7 (1.5 mg, 9 %) as a pale colored oily product. HRMS (ESI-TOF): molecular
formula, C15H22N2O6S2; [M-H+]-: 389.0847(calc. 389.0847); 1H NMR (400 MHz, MeOD) δ: 1.81-1.85
(m, 2H, H-2'),2.31 (s, 3H, CH3-),2.25-2.30 (m, 2H, -CO-S-CH2-CH2-CH2-S-),2.54 (t, 2H, -CO-S-CH2-CH2CH2-S-), 2.95 (t, 2H, -CO-S-CH2-CH2-CH2-S-),3.41(s, 2H, C5-CH2-S),3.76-3.80 and 3.95 (m, 3H, H-3'
and H-5'), 4.43 (m, 1H, H-4'), 6.29 (t, J1'-2'= 8 Hz, 1H, H-1'), 8.01 (s, 1H, H-6);

13C

NMR (100 MHz,

MeOD) δ: 28.47, 28.94. 30.33, 30.74 and 31.45 (CH3-CO-S-CH2-CH2-CH2-S-CH2-C5), 41.54 (C-2'),
62.95 (C-5'), 72.34 (C-3'), 86.63 (C-4'), 89.01 (C-1'), 112.92 (C-5), 139.38 (C-6), 152.15 (C2=O),
165.11 (C4=O), 197.60 (CH3-C=O).
6.2.2 Synthesis of S-Mercaptopropyl-5-(Mercaptomethyl)-2'-Deoxyuridine-5'Triphosphate
Synthesis of S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate,
AcSTTP

(9, scheme 6.2):S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine [(7, scheme

6.1) 5 mg, 0.013 mmol] was weighed in a 10 mL r.b. flask and dried overnight under vacuum. 2chloro-4H-1,3,2-benzodioxaphosphorin-4-one (5 mg, 2 eq.) was dried in another flask for 10 min.
Tri-n-butylammonium pyrophosphate (30 mg, 5 eq.) was dried overnight in a separate flask, under
high vacuum. The pyrophosphate was dissolved in DMF (0.3 mL) with additional TBA (0.1 mL). The
2-chloro-4H-1,3,2-benzodioxa-phosphorin-4-one was dissolved in DMF (0.2 mL) and transferred
into the flask containing pyrophosphate under argon. A lot of argon was flushed through the reaction flask as the mixture was allowed to react at room temperature. The mixture was allowed to stir
at room temperature. After 45 min the mixture was transferred into the flask containing vacuum
dried compound 7 dissolved in DMF (0.2 mL) and toluene (0.1 mL). The combined contents were
allowed to stir at room temperature for 4 h to yield the cyclic phosphite intermediate 8 (scheme
6.2). The cyclic-phosphite 8 was then oxidized by adding iodine solution (0.02%
I2/THF/Pyridine/H2O, 1 mL). The mixture was stirred for 1 h and then hydrolyzed with water (5
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mL) and allowed to stir at room temperature for 4 h to ensure complete hydrolysis. The sample was
precipitated using NaCl (0.3 M)/ ethanol (3 volumes). The precipitate was analyzed by recording a
TLC (5:3:2 of iso-PrOH:NH3.H2O:H2O). The crude S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'deoxyuridine-5'-triphosphate,

AcSTTP,

9 was then purified by reverse phase HPLC. HR-MS (ESI-

TOF): molecular formula, C15H25N2O15P3S2; [M-2H++Na+]-: 650.9647 (calc. 650.9656); 1H NMR (400
MHz, D2O) δ: 1.82-1.86 (m, 2H, H-2'), 2.34 (s, 1H, CH3-), 2.37-2.40 (m, 2H, -CO-S-CH2-CH2-CH2-S-),
2.59-2.63 (t of d, 2H, -CO-S-CH2-CH2-CH2-S-), 2.92-2.96 (t of d, 2H, -CO-S-CH2-CH2-CH2-S-), 3.53(s,
2H, C5-CH2-S), 4.19-4.20 (m, 3H, H-3' and H-5'), 4.67 (br, 1H, H-4'), 6.34 (t, J1'-2'= 6.72 and 7.0 Hz, 1H,
H-1'), 7.90 (s, 1H, H-6);13C NMR (100 MHz, D2O) δ: 28.50, 28.59 and 28.90 (-CO-S-CH2-CH2-CH2-S-),
30.66 and 30.86 (CH3-CO-S- and C5-CH2-S-), 39.59 (C-2'), 66.29 (C-5'), 71.67 (C-3'), 86.03 (C-4'),
86.51 (C-1'), 112.98 (C-5), 139.33 (C-6), 152.34 (C2=O), 165.66 (C4=O), 202.28 (CH3-C=O); 31P NMR
(162 MHz, D2O) δ: -23.39 (t, Jβ = 19.44 Hz, 1P, P-β), -11.84 (d, Jα = 21.06 Hz, 1P, P-α), -10.97 (d, Jγ =
19.44 Hz, 1P, P-γ).
Synthesis of S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate, HSTTP
(10, scheme 6.2): S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate,
AcSTTP

tecting

was treated with NH3 (1 % in MeOH) for 12 h at room temperature to depotect the thiol proacetate

group

to

yield

S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-

triphosphate, HSTTP (10, scheme 6.2). The sample was purified by precipitating using NaCl (0.3 M)/
ethanol (3 volumes). 1H NMR (400 MHz, D2O) δ: 1.90 (b, 2H, H-2'), 2.41 (b, 2H, -CO-S-CH2-CH2-CH2S-), 2.67 and 2.74 (b, 4H, -CO-S-CH2-CH2-CH2-S-), 3.55 (s, 2H, C5-CH2-S), 4.19 and 4.22 (b, 3H, H-3'
and H-5'), 4.68 (br, 1H, H-4'), 6.31 (b, 1H, H-1'), 7.91 (s, 1H, H-6);13C NMR (100 MHz, D2O) δ: 28.06,
29.66 and 36.45 (HS-CH2-CH2-CH2-S-), 38.65 (C-2'), 65.13 (C-5'), 70.24 (C-3'), 85.23-85.57 (C-4' and
C-1'), 112.19 (C-5), 138.59 (C-6), 151.49 (C2=O), 164.87 (C4=O);

31P

NMR (162 MHz, D2O) δ: -21.76

(t, Jβ = 18.8 and 20 Hz, 1P, P-β), -11.38 (d, Jα = 19.3 Hz, 1P, P-α), -6.14 (d, Jγ = 19.8 Hz, 1P, P-γ).
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6.2.3 HPLC Analysis and Purification
The crude AcSTTP (9)was purified and analyzed by reversed-phase high performance liquid
chromatography (RP-HPLC). The AcSTTP was eluted at 260 nm, with a flow-rate of 6 mL/min [buffer
A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 5 % buffer B to 40 % buffer B in 20 min, reaching 100 % buffer B in 30 min.. The
desired peak was collected and the buffer was removed by lyophilization. All samples were analyzed on Welchrom C18-XB column (4.6*250 mm) and measured at a flow rate of 1.0 mL/min and a
linear gradient of 0 to 25 % buffer B in 20 min [buffer A: 20 mM TEAAc (pH 7.1) in water; buffer B:
20 mM TEAAc (pH 7.1)in 50% acetonitrile]. The colorless precipitates of HSTTP (10) were also analyzed at 260 nm with a flow rate of 1.0 mL/min and a linear gradient of 0 to 25 % buffer B in 20 min
(figure 6.1).
6.2.4 UV-Vis Absorption Study
All absorption spectra were recorded in de-ionized water (figure 6.2). The baseline was
subtracted at all times.
6.2.5 Synthesis of Oligonucleotides
The DNA primer (P) and template (T) sequences (table 6.1) were synthesized on an automated Applied BioSystem 394 DNA Synthesizer (Applied Biosystems, Foster City, CA) employing
standard β-cyanoethylphosphoramidite chemistry (1 μmol scale). Oligonucleotides were synthesized in DMTr-off mode, with average coupling efficiency greater than 99%. The oligonucleotides
were de-protected in concentrated NH4OH (55 °C, 16 h), and purified by 19% denaturing polyacrylamide gel electrophoresis. The gel was visualized under UV light, crushed and soaked in water.
The oligonucleotides were recovered from water solution by NaCl (0.3 M)/ ethanol (3 volumes)
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precipitation. Oligonucleotides were quantified by UV-Vis absorbance at 260 nm using standard
molar extinction coefficients and characterized by MALDI-TOF MS.

6.2.6 Enzymatic Incorporation Studies
DNA primers were labeled at the 5'-terminus by incubating in the presence of γ-[32P]-ATP
(Perkin Elmer, Boston, MA) and T4 polynucleotide kinase (New England Biolabs, Beverly, MA) for 1
h at 37 °C. Polymerase reactions were carried out by adding klenow exo-minus DNA polymerase
(Epicentre Biotechnologies, Madison, WI) to a premixed solution containing DNA primer(s) (P1 or
P2, table 6.1) and DNA template(s) (T1, T2 or T3, table 6.1), dNTPs (dATP, dCTP and dGTP, Epicentre Biotechnologies, Madison, WI), dNTP substrate (TTP/

AcSTTP/ HSTTP)

and DTT in klenow exo-

minus DNA polymerase 10X reaction buffer at 37 °C. The reaction mixtures were incubated at 37 °C
and quenched by the addition of the gel loading dye solution (10 μL each, containing 50 % glycerol,
0.60 % xylene cyanol, 0.60 % bromophenol blue, 20 mL of 1 mM EDTA, saturated urea). The analysis was performed on 19%, polyacrylamide gel electrophoresis (PAGE). For single nucleotide enzymatic incorporation reactions, no other dNTPs, except for substrate dNTPs (TTP/ AcSTTP/ HSTTP),
were added to the reaction mixture. The reaction mixtures were incubated at 37 °C for desired time
and analyzed on 19%, polyacrylamide gel. Polymerase reactions contained primer (1.5 μM), template (3 μM), dNTPs (0.1 mM each), DTT (5 mM), and 10X reaction buffer (1X) in a final reaction
volume of 5 μL.
6.3 Results and Discussion
6.3.1 Synthetic Design
S-(3’-S-acetylpropyl)-5-(mercaptomethyl)-2'-deoxyuridine was synthesized from thymidine
in seven steps as shown in scheme 6.1. Compounds 1, 2 and 3 were synthesized by using literature
reported methodology (249). The free 3'- and 5'- hydroxy groups on thymidine were protected with

73
tert-butyldimethylsilyl protecting group. It was a clean and efficient reaction yielding 98 % of pure
3',

5'-bis-O-(tert-butyldimethylsilyl)-thymidine.

3',

5'-bis-O-(tert-butyldimethylsilyl)-5-

bromomethyl-2'-deoxyuridine(2) was obtained by radical bromination at benzylic position using Nbromosuccinimide under reflux conditions, in the presence of catalytic amounts of benzoyl peroxide. Residual insoluble succinimide was removed by filtration. Compound 2 was used immediately
without any purification. S-acetyl-3', 5'-bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'deoxyuridine(3) was obtained by the nucleophilic substitution of bromide with thioacetate. Alkaline hydrolysis of compound 3, using NaOH in MeOH, afforded 3',5'-bis-O-(tert-butyldimethylsilyl)5-(mercaptomethyl)-2'-deoxyuridine (4). Since naked/un-protected thiol-compounds have a strong
tendency to dimerize, any characterization or purification on compound 4 was difficult. So the sample was used as such for the next step. The dimer of compound 4 was reduced in situ using
dithiothreitol (DTT). The reaction was performed in an oxygen free, argon rich atmosphere. Alkylation of the free thiol anion thus generated, using 1, 3-dibromopropane, afforded S-(3’bromopropyl)-3', 5'-bis-O-(tert-butyldimethylsilyl)-5-(mercaptomethyl)-2'-deoxyuridine(5). Compound 5 is a stable intermediate. S-(3(acetylthio)propyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-5(mercaptomethyl)-2'-deoxy-uridine (6) was obtained by the nucleophilic substitution of bromide
with thioacetate. Selective 3', 5'-bis-O-desilylation of compound 6, using triethylamine
trihydrofluoride (TEA.3HF) in THF, yielded S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'deoxyuridine (7).
S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine (7) was used to synthesize S(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate (AcSTTP, 9, scheme
6.2).11, as shown in figure 14.3. It was observed that the addition of toluene to the nucleoside 7 is
crucial as earlier attempts to synthesize triphosphate, by dissolving 7 in DMF or DMF/1,4-dioxane
(1:1) mixture, failed. Only when the nucleoside was dissolved in DMF/toluene (2:1) mixture, triphosphate formation was observed. We believe that the toluene interacts with the bulky base and
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helps it to stack better, making 5'-OH more available for phosphorylation yielding cyclic phosphate
intermediate 8. S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate (HSTTP,
10) was obtained by deprotection of the thiol-protecting acetate group with ammonia.

Scheme 6.1 Synthesis of S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine (7)
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Scheme 6.2 Synthesis of S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate, HSTTP (10).

6.3.2 HPLC Purification and Analysis
The crude AcSTTP (9)was purified and analyzed by RP-HPLC. The AcSTTP was eluted at 260
nm, with a flow-rate of 6 mL/min [buffer A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM
TEAAc (pH7.1) in 50% acetonitrile] and a linear gradient from 5 % buffer B to 40 % buffer B in 20
min. The desired peak was collected and the buffer was removed by lyophilization. All the dry fractions of AcSTTP and precipitated HSTTP were analyzed on Welchrom C18-XB column (4.6*250 mm)
and measured at a flow rate of 1.0 mL/min and a linear gradient of 0 to 25 % buffer B in 20 min
[buffer A: 20 mM TEAAc (pH 7.1) in water; buffer B: 20 mM TEAAc (pH 7.1) in 50% acetonitrile
(figure 5.1). The compounds being structurally similar have a small, but measureable, difference in
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their retention times on the column. A RP-HPLC analysis of purified

AcSTTP

and

HSTTP,

at 260 nm

wavelength, is presented in figure 6.1.

Figure 6.1 RP-HPLC analysis of AcSTTP and HSTTP: HSTTP (red curve, retention time: 24.75 min); AcSSTTP (blue curve, retention time: 24.96 min) and co-injection of AcSTTP and HSTTP (black curve, retention times: 24.75 and 24.96 min, respectively).

6.3.3 Absorption Properties
The native thymidine-5'-triphosphate (TTP) shows an absorption maximum at ~267 nm.
The modification at the C5-methyl of the thymine base does not alter the absorption properties of
the resultant nucleobase. Hence, S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine-5'triphosphate

(AcSTTP,

9)

and

S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-

triphosphate, (HSTTP,10) have similar absorption profiles (figure 6.2).
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Figure 6.2 Absorption spectra of TTP (—), AcSTTP (—), and HSTTP (—) in water at 25 ˚C.

.

6.3.4 Enzymatic Incorporation of TTP, AcSTTP and HSTTP into DNA
To investigate the incorporation efficiency of S-(3(acetylthio)propyl)-5-(mercaptomethyl)2'-deoxyuridine-5'-triphosphate

(AcSTTP,

9)

and

S-mercaptopropyl-5-(mercaptomethyl)-2'-

deoxyuridine-5'-triphosphate, (HSTTP,10) into DNA, polymerization reactions were performed in
the presence of klenow exo minus DNA polymerase (Kf-). A list of DNA primers and templates used
for the primer extension reactions is presented in table 6.1.
Table 6.1 Sequences of DNA primers and templates used for the enzymatic incorporation of TTP, AcSTTP and HSTTP. The
underlined bases are the sites for incorporation of TTP, AcSTTP and HSTTP.
Primers:

P1 (17-mer) 5'-d-TAG CGG GTT GCT GGT GG -3'
P2 (21-mer) 5'-d-GCG TAA TAC GAC TCA CTA TAG-3'

Templates:T1 (21-mer) 3'-d-ATC GCC CAA CGA CCA CCA TGG- 5'
T2 (23-mer) 3'-d-ATC GCC CAA CGA CCA CCAAAT GG- 5'
T3 (55-mer) 3'-d-CGC ATT ATG CTG AGT GAT ATC CGT TGG ACT ACT CCG GCT TTC CGG CTT TGC ATG T -5'

78

Figure 6.3 Enzymatic incorporation of a single nucleotide (TTP, AcSTTP and HSTTP) into DNA (T1): (a) Enzymatic incorporation of TTP, AcSTTP and HSTTP by Klenow exo(-) on DNA template T1. Gel electrophoresis autoradiography of the
polymerization reaction with (b) Kf-= 0.0015 U/µL and reaction time = 60 min for TTP and 90 min for AcSTTP and HSTTP,
(c) Kf-= 0.00075 U/µL and reaction time = 60 min, (d) Kf-= 0.0015 U/µL and reaction time = 30 min, and (d) Kf-= 0.00075
U/µL and reaction time = 30 min.

The DNA polymerization was performed with primer (1.5 μM), template (3 μM), TTP/
AcSTTP/ HSTTP

(0.1 mM), and Klenow exo(-) DNA polymerase (varying amounts) and analyzed by

19% polyacrylamide gel electrophoresis (figures 6.3, 6.4 and 6.5). Like TTP, AcSTTP and HSTTP also
act as fine substrates for DNA polymerases. Single nucleotide incorporation of the TTP,
HSTTP

AcSTTP

and

into DNA was studied using a short, 21 nt long DNA template (T1) and the results are shown

in figure 6.3. As evident from the autoradiographs obtained,

AcSTTP

acts as a better substrate than
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by TTP and HSTTP: under different reaction times and with different enzyme concentrations, AcSTTP
always terminates polymerization after the incorporation of a single nucleotide (n + 1 DNA, figure
6.3, lane 4) whereas TTP and HSTTP either result in the formation of n + 2 DNA product or a mixture
of desired n + 1 DNA along with some n + 2 DNA (figure 6.3, lanes 2 and 3, respectively). From the
intensity of the product DNA band it appears that both, AcSTTP and HSTTP, are well recognized by the
DNA polymerase. With the modified DNA moving slower than the native DNA, there is a measureable structural impact of the modification on the product mobility. The single nucleotide incorporation will be further confirmed by MALDI-MS analysis.
The DNA template T2 was designed to study the efficiency of incorporation of three consecutive modified bases. The 17 nt long primer P1 was enzymatically extended to a 20 nt DNA product
by incorporating three consective thymidine bases over the template T2. The DNA polymerization
was performed with primer (1.5 μM), template (3 μM), TTP/ AcSTTP/ HSTTP (0.1 mM), and Klenow
exo(-) DNA polymerase (0.0015 U/µL) and analyzed by 19% polyacrylamide gel electrophoresis
(figure 6.4). The reaction was incubated for 5 min with TTP as a substrate (figure 6.4, lane 2)
whereas the reactions with AcSTTP and HSTTP as substrates, the incubation time was 60 min (figure
6.4, lanes 3 and 4, respectively). Under these experimental conditions, AcSTTP appears to be the best
substrate for DNA polymerase.
We also studied the efficiency of incorporation using a longer DNA template (T3). The incorporation was carried out by extending a 21 nucleotide primer along a 55 nucleotide template.
The DNA polymerization was performed with primer (1.5 μM), template (5 μM), TTP/
HSTTP

AcSTTP/

and other dNTPs (0.1 mM), and Klenow exo(-) DNA polymerase (0.04 U/μL) and analyzed by

19% polyacrylamide gel electrophoresis. Figure 3.8 shows the primer extension using T2 template.
This polymerization involved the incorporation of three TTP/ AcSTTP/ HSTTP (figure 6.5).
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Figure 6.4 Enzymatic incorporation of three consecutive bases (TTP, AcSTTP and HSTTP) into DNA (T2): (a) Enzymatic
incorporation of TTP, AcSTTP and HSTTP by Klenow exo(-) on DNA template T2. (b) Gel electrophoresis autoradiography of
the polymerization reaction with Kf-= 0.0015 U/µL and reaction time = 5 min for TTP (lane 2) and 60 min for AcSTTP (lane
4) and HSTTP (lane 3).

Figure 6.5 Enzymatic incorporation of all natural dNTPs, TTP, AcSTTP and HSTTP into DNA (T3): a) Enzymatic incorporation of all dNTPS, TTP, AcSTTP and HSTTP by Klenow exo(-) on DNA template T3;(b) Gel electrophoresis autoradiography
of the polymerization reaction with Kf- = 0.0015 U/µL and reaction time = 60 min for TTP (lane 3) and 90 min for AcSTTP
(lane 5) and HSTTP (lane 4).
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6.3.5 Other Proposed Studies
The synthesized and purifiedAcST-DNA and HST-DNA will be used to study the stabilization of
gold nanoparticles with reference to the native DNA. The study will be based on the strong affinity
of gold nanoparticles for thiol-functionality.
AcST-DNA

HST-DNA

will be used as such to reduce gold whereas

will be hydrolyzed in-situ with ammonia to generate free thiol-group for gold nanoparti-

cle stabilization. The modified DNA will also find use and application in DNA/RNA microchip surface functionalization for rapid detection of pathogens.
6.4 Conclusions and Future Prospects
We have successfully synthesized a novel nucleoside, S-(3(acetylthio)propyl)-5(mercaptomethyl)-2'-deoxyuridine, from thymidine. This modified nucleoside was successfully
used to synthesize S-(3(acetylthio)propyl)-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate
and S-mercaptopropyl-5-(mercaptomethyl)-2'-deoxyuridine-5'-triphosphate. Both the forms of the
triphosphates are efficient substrates for DNA polymerases. The polymerase recognition and incorporation efficiency of the modified triphosphates, relative to the native, has also been effectively
demonstrated by the use of different combination of DNA primers and templates. The modified
DNA thus obtained will be further used for gold nanoparticle stabilization. The modified DNA will
also find use and application in DNA/RNA microchip surface functionalization for rapid detection of
pathogens.
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